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Norsk sammendrag 
 
 
 
Bronkial mikrodialyse 
 
I denne avhandlingen beskrives utviklingen av en ny metode for kontinuerlig overvåkning av 
sammensetningen av væskefilmen som kler luftveiene i de minste bronkiene i store dyr og 
mennesker (bronkial mikrodialyse). Utgangspunktet var ideen om at eksisterende metoder 
hadde vesentlige begrensninger. Ideen var å finne en metode for kontinuerlig måling som ikke 
skadet pasienter. Metoden skulle evalueres under overvåking av lungepåvirkning etter 
eksperimentell avklemming-gjenoppretting av tarm sirkulasjonen og under aortakirurgi. 
 
Det første arbeidet evaluerte mikrodialyse i bronkiene og blod i et eksperimentelt oppsett med 
kontrollert blod-konsentrasjonen av et lite molekyl og et større molekyl. Vi konkluderte med 
at bronkial microdialyse kunne måle konsentrasjonen av molekyler i væskefilmen som kler 
luftveiene i de minste bronkiene. Bruken av en endogen korreksjonsfaktor (urea) forbedret 
nøyaktigheten. 
I det andre arbeidet ble bronkial mikrodialyse brukt for å beskrive den inflammatoriske 
responsen i bronkiene i en grise-modell med avklemming-gjenoppretting av tarm 
sirkulasjonen. Vi fant en økning i den bronkiale konsentrasjonen av inflammatoriske 
molekyler i løpet av de første 60 minuttene av perioden med gjenopprettet tarm sirkulasjon. 
Det tredje arbeidet var en studie av inflammatorisk respons hos pasienter som gjennomgikk 
planlagt kirurgi for utposning på hovedpulsåren. Et bredt spektrum av inflammatoriske 
molekyler ble målt i bronkiene og i blod under og umiddelbart etter operasjonen. 
Inflammatoriske molekyler økte i løpet av de første 60 minutter av gjenopprettet sirkulasjon 
etter at pulsåre-graftet var på plass.  
 
Avhandlingen konkluderer med å svare på forskningsspørsmålene: Bronkial microdialyse er 
gjennomførbart hos gris og mennesker og er i stand til å måle dynamikken i inflammatoriske 
molekyler i bronkiene uten registrerte skader. Men metoden trenger videre evaluering og 
utvikling for å støtte riktige klinisk beslutninger på et tidligere tidspunkt enn det som er mulig 
med de metoder som er tilgjengelige i klinikken i dag. 
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Summary 
This thesis describes the stepwise development of a new method for monitoring the dynamic 
composition of the epithelial lining fluid in bronchi in large animals and humans. The starting 
point was the belief that existing methods had significant limitations. Existing methods were 
invasive and their use created lung injury or failed to measure substances of interest. The idea 
was to find a method for continuous measurement that did not harm patients. The method was 
to be evaluated monitoring lung involvement in organ crosstalk after experimental intestinal 
ischemia-reperfusion injury and during aortic surgery. 
 
The first paper evaluated microdialysis in the bronchi and blood in an experimental setting 
with controlled blood-concentration of one small substance (lactate) and one larger substance 
(fluorescein-isothiocyanate-dextran 4000Da). We concluded that bronchial microdialysis 
could measure concentration of substances within the bronchial epithelial lining fluid. The use 
of the concentration gradient of an endogenous correction factor (urea) improved the 
accuracy. In the second paper we used bronchial microdialysis to describe the inflammatory 
response in the bronchi in a pig model of intestinal ischemia-reperfusion injury. We found an 
increase in the bronchial concentration of inflammatory mediators within the first 60 minutes 
of intestinal reperfusion after intestinal ischemia. The third paper was a study of the 
inflammatory response in patients undergoing aortic surgery. A broad spectrum of 
inflammatory markers was measured in bronchi and blood during and immediately after 
surgery. Inflammatory mediators increased within the first 60 minutes of reperfusion of the 
lower body when the aortic graft was in place. The concentrations of seventeen out of 
eighteen inflammatory mediators, as measured by bronchial microdialysis, were significantly 
different in patients suffering organ failure directly after surgery. 
 
The thesis concluded by answering the thesis questions and claims that bronchial 
microdialysis is feasible in pigs and humans, can be done with no registered complications 
and is able to measure the dynamics of inflammatory mediators in the bronchi. However the 
method needs further evaluation of methods to ease secure placement of the probe, measure 
the absolute concentration of substances in the bronchial epithelial lining fluid. The delay in 
analysis of cytokines needs to be significantly reduced to take advantage of the results in 
support for expedited clinical judgement. 
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Abbreviations 
 
AAA abdominal aortic aneurysm IL interleukin 
AECC American European Consensus Conference IR ischemia-reperfusion 
ATP adenosine triphosphate MCP monocyte chemotactic protein 
ALI acute lung injury MIP macrophage inflammatory protein 
ARDS acute respiratory distress syndrome MOF multiple organ failure 
ARF acute respiratory failure MPAP mean pulmonary artery pressure 
BAL bronchial alveolar lavage 
Na+-K+ 
ATPase 
sodium-potassium pump 
BALF bronchial alveolar lavage fluid NF- nuclear factor-kappa B 
cGMP cyclic guanosine monophosphate NO nitric oxide 
CPAP continuous positive airway pressure N-PCP-III N-terminal procollagen peptide-III 
CT X-ray computer tomography NAD+/NADH nicotinamide adenine dinucleotide 
DAD diffuse alveolar damage AAA abdominal aortic aneurysm 
EE extraction efficiency PAI-1 plasminogen activator inhibitor-1 
ELF epithelial lining fluid PEEP positive end-expiratory pressure 
ENaC epithelial sodium channel PMN polymorphonuclear neutrophils 
FD-4 fluorescein isothiocyanate dextran 4000Da RCT randomized controlled trials 
GFR glomerular filtration ratio SMA superior mesenteric artery 
G-CSF granulocyte colony-stimulating factor TGF transforming growth factor 
GM-CSF 
granulocyte macrophage colony-stimulating 
factor 
TNF tumor necrosis factor 
HSP heat shock protein VEGF vascular endothelial growth factor 
IFN interferon 
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Introduction 
The living organisms general response to ischemia-reperfusion (IR), trauma, bleeding, 
infection, transfusion, transplantation, heat and cold is a host defense response. The host 
defense response comes from the innate immune system and is characterized by a non-
specific, immediate maximal, humoral, cell-mediated and neuronal response[1, 2]. 
This thesis is dedicated to improve the method of monitoring of the bronchial epithelial lining 
fluid (ELF) and thereby better describe the immediate inflammatory response in the lung as a 
response to distant IR injury as measured by cytokines. This piece in the large puzzle of the 
innate immune response has intrigued researchers and clinicians for decades. 
""&  ! !!!"
The lung responds to distant trauma with a variety of presentations. Generally the severity of 
the lung failure varies with the severity of the trauma, but to a large degree the response also 
varies between individuals exposed to similar trauma. The clinical presentation of lung failure 
can be mild and transient resolving within 24 hours or with severe dysfunction in both the 
oxygenation and ventilation function. These presentations are stratified in the scientific 
literature as acute respiratory failure (ARF), acute lung injury (ALI) or acute respiratory 
distress syndrome (ARDS). 
#"
One of the major problems with research on lung injury in response to distant trauma is the 
lack of unique and accurate definitions. 
ARF is a problematic denomination since it is not uniquely defined. The most common 
criteria used are defining oxygenation failure, ventilatory failure or the need for endotracheal 
intubation and mechanical ventilation: 
1. PaO2/FiO2-ratio less than 26.7 kPa[3]. 
2. Hypoxia <8kPa and/or hypercarbia >6.5 kPa[4]. 
3. Endotracheal intubation and mechanical ventilation  24 hours[5].  
 
ARDS was first defined by Ashbough in 1967[6]. A new and expanded consensus definition 
of ALI and ARDS came in 1994 and has been used of clinicians and researchers until this 
year, table A[7]. 
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Table A. American European Consensus Conference criteria for ALI and ARDS (1994)[7]. 
 
Timing Acute onset 
Oxygenation ALI: Pao2/FiO2 <300 mm Hg (<40kPa) 
  ARDS: Pao2/Fio2 <200 mm Hg (<26.7kPa) 
  Regardless of positive end-expiratory pressure (PEEP) 
Chest radiograph Bilateral infiltrates seen on frontal chest radiograph 
Pulmonary artery wedge pressure <18 mmHg when measured or no clinical evidence of 
left atrial hypertension 
 
“However, after 18 years of applied research, a number of issues regarding various criteria of 
the AECC definition have emerged, including a lack of explicit criteria for defining acute, 
sensitivity of PaO2/FIO2 to different ventilator settings, poor reliability of the chest radiograph 
criterion, and difficulties distinguishing hydrostatic edema”, and to address the previous 
limitations this year the new Berlin criteria for ARDS was presented[8], table B. 
 
Table B. The Berlin definition of ARDS (2012)[8].  
 
Timing  Within 1 week of a known clinical insult or new or worsening respiratory symptoms. 
Chest imaginga  Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules. 
Origin of edema 
 
Respiratory failure not fully explained by cardiac failure or fluid overload. 
Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if  
no risk factor is present. 
Oxygenationb 
Mild 200 mmHg < PaO2/FiO2  300 mmHg with PEEP or CPAP 5 cm H2Oc 
Moderate 100 mmHg < PaO2/FiO2  200 mmHg with PEEP 5 cm H2O 
Severe  PaO2/FiO2  100 mmHg with PEEP 5 cm H2O 
Abbreviations: CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen; PaO2, partial 
pressure of arterial oxygen; PEEP, positive end-expiratory pressure. 
aChest radiograph or computed tomography scan. 
bIf altitude is higher than 1 000 m, the correction factor should be calculated as follows: (PaO2/FiO2 x 
(barometric pressure/760)). 
cThis may be delivered noninvasively in the mild acute respiratory distress syndrome group. 
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
Luhr et al found the incidence in Scandinavian countries to be for ARF 77.6/100 000, ALI 
17.9/100 000 ARDS 13.5/100 000 which is in accordance to findings in similar studies from 
Europe and Northern America[5, 9]. 

!##(!#(
Luhr et al found mortality of ARF (41%) to be similar to the mortality of ALI and ARDS[10–
13]. According to two meta-analysis papers from 2008-2009 mortality of ARDS was 43-
44%[5]. Phua et al points out that the mortality was lower in randomized controlled trials 
(RCTs) in fact 36% and that there were no reduction in mortality after 1994[14, 15]. Zambon 
and Vincent found a reduction in mortality of 1.1% per year in the period 1994-2006[15]. In a 
review published in 2012, Matthay et al refers to trials where the ARDS network has tested 
new interventions as low tidal volume ventilation, conservative fluid therapy and enteral 
additives (omega-3, gammalinolenic acid and antioxidants) and found reduced mortality from 
36 to 22% in the period from 1996 until the most recent presented trials[14]. 
Morbidity and mortality in ARF, ALI and ARDS are mainly caused by multiple organ failure 
(MOF)[16]. In a recent 5 year follow up study Herridge et al found pulmonary function to be 
normal or near normal, but physical capacity were reduced and recovery was slower in older 
versus younger patients[17]. Bienvenu et al found an accumulated incidence of depression of 
40% and physical impairment of 66 % the first two years after ALI[18]. 
Hopkins et al found that neurocognitive function was reduced in 70% at hospital discharge 
and in about 50 % in 1 and 2 year follow up. Quality of life was still reduced at 2-year follow 
up[19]. 
#(*#""#("(
There is no uniformly accepted description for ARF. ALI and ARDS have been extensively 
described and this section will deal with these conditions. 
Causes are divided into direct (pulmonary) and indirect (extrapulmonary). Direct causes are 
amongst others pneumonia, aspiration of gastric contents, inhalational injury, fat embolism, 
near drowning and reperfusion injury after lung transplantation and lung embolectomy. 
Examples of indirect causes are sepsis, severe trauma, transfusion of blood products, 
cardiopulmonary bypass, vascular surgery with IR, drug overdose and pancreatitis[10–13, 
20]. 
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In the acute phase (circa day 1 to 6), the exudative phase, there is alveolar and interstitial 
edema with accumulation of polymorphonuclear neutrophils (PMN), macrophages and red 
blood cells (RBC) in the alveoli. Lung endovascular injury and lung epithelial injury causes 
hyper-permeability. Hyper-permeability allows protein-rich fluid to flow into the lung 
interstitium and the alveoli, and establish interstitial and alveolar edema. The lung is affected 
with disturbed gas-exchange, reduced lung compliance, increased work of breathing and 
mismatch of ventilation and perfusion[21]. The lung tissue present with diffuse alveolar 
damage (DAD), accumulation of PMNs, disrupted epithelial integrity, denuded basal 
membrane, pulmonary edema, fibrin depositions, endothelial injury and micro-thrombi[16]. 
In the sub-acute phase (circa day 7 to 14) there are signs of repair with proliferation of lung 
epithelial type II cells, occurrence of lung fibroblasts and start of collagen deposition. 
In the chronic phase, the fibro-proliferative phase, there is resolution of the acute PMN 
infiltrate and edema. There are increased numbers of mononuclear cells and alveolar 
macrophages. In some patients there are fibrosis, but in many patients resolution progresses 
without fibrosis[16, 22]. 
!!  
The edematous lung parenchyma and airways filled with secretions result in non-ventilated 
alveoli. The gas in these areas is resorbed with resulting consolidated lung. Atelectasis cause 
ventilation-perfusion mismatch with shunting of deoxygenated blood[21, 23]. 
"!
Coagulation and inflammation interacts during secondary ARF, ALI and ARDS. The initial 
trauma initiates an imbalance between pro- versus anti-coagulants and fibrin building versus 
fibrinolytic activity. Deposition of intra-alveolar fibrin inactivates surfactant and acts as and 
chemo-attractant of PMNs. Pro-coagulant activity is characterized with increased activity of 
tissue factor and factor VIIa. Decreased fibrinolytic activities are due to inhibition of 
plasminogen activators (urokinase and tissue type) by plasminogen activator inhibitor -1 and 
blockage of plasmin by 2-plasmin inhibitor[24, 25]. 
The outcomes are microthrombosis and diffuse endothelial dysfunction/damage.  

&" !! 
The PMN pathway is the best described in secondary lung failure. The activation of PMNs is 
a major factor in the development, persistence and outcome of ARDS. PMNs in conjunction 
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with platelets cause lung endothelial damage. In experimental studies with PMN depletion 
and inhibition of chemo-attractants the severity of lung injury was reduced[26]. 
In the blood stream activated PMNs release pro-inflammatory and pro-coagulant mediators, 
reactive oxygen species and proteases. Leukotrienes, thromboxanes and prostaglandins, 
metabolites from arachidonic acid are released. The result is aggregation of platelets and 
leukocytes and vascular constriction. Obliteration of pulmonary vessels cause dead space 
ventilation and subsequent ventilation-perfusion mismatch[27]. 
In response to distant trauma endothelial cells express increased activity of the transcription 
factor nuclear factor- (NF- ) and this causes increased expression of adhesion molecules 
on the endothelial surface (intercellular adhesion molecule-1, vascular adhesion molecule-1). 
2-Integrins are expressed on endothelial cells and interacts with adhesion molecules in the 
migration of PMNs from blood to the interstitium[27]. 
In patients undergoing open abdominal aortic aneurysm (AAA) repair the concentration of 
PMNs in vena cava are found to higher than on the arterial side[28]. This was interpreted as 
an indication of removal of activated PMNs in the pulmonary circulation. 
"  "!"#!!
The affection of the lung parenchyma is heterogeneous with regional atelectasis and regional 
thrombosis. The ventilation-perfusion mismatch leads up to reduced oxygenation of arterial 
blood. The choice of ventilator strategy to overcome this challenge is still under debate. There 
is general agreement upon a strategy with low tidal volumes (6(-8)ml)[29]. Still the question 
of optimal positive end expiratory pressure (PEEP) question is unsettled. Some studies 
support that moderate PEEP prevent over-distension of alveoli that are open. Other studies 
suggest more aggressive recruitment maneuvers and higher PEEP to open the lung and keep it 
open to avoid “atelectrauma” with shear stress forces on airways during cyclic closing and 
reopening[30–32].  

"&! 
Pulmonary hypertension appear early in the course of ALI, ARDS and ARF. The pulmonary 
hypertension is a result of several factors. 
The lung endothelium produce mediators that regulates vascular tone (endothelins, 
prostanoids and nitric oxide) and metabolize vasoactive mediators as angiotensinogen-I by 
angiotensinogen converting enzyme. In ALI there is a shift towards increased vascular tone. 
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With edema formation and atelectasis some lung regions are poorly ventilated. In hypoxic 
lung-regions the compensatory mechanism of pulmonary hypoxic vasoconstriction shifts 
blood to ventilated regions leading to reduced ventilation-perfusion mismatch[33].  
The pro-coagulant state as discussed earlier results in diffuse micro-thrombi and infarctions. 
In addition cellular sequestration contributes to capillary occlusion. 
Interstitial edema compresses capillaries. Positive pressure ventilation with high PEEP and 
plateau pressure may add to this effect. 
  &""
The cascades of cytokines, coagulation factors and growth factors are closely related and 
interconnected. The mediators of inflammation interact with lung tissue and alter function. 
Lung endothelium and epithelium are activated. With progress of inflammation dysfunction 
and disruption evolves. In the early phase there is an increased amount of fluids in the lung 
interstitium and alveoli. This is caused by increased leakage through the lung endothelium 
and epithelium. There is also decreased transport of salt and water from the alveoli and into 
the lung interstitium.  
!(#"
Altered concentrations of cytokines have been found to correlate to the risk for development 
of ALI and ARDS.  
Donnelly found bronchial alveolar lavage fluid (BALF) IL-8 > 200 pg/ml to be predictive of 
for the development of ARDS in intensive care unit patients at risk[34]. In a recent study 
Raymondos et al found that patients with BALF IL-8 > 200 pg/ml also had increased BALF 
concentrations of IL-6, TNF-, IL-1, IL-10 and IL-1ra levels. Plasma pro-inflammatory 
cytokines were also increased[35]. In a study of ARDS and non-ARDS patients admitted to 
the intensive care unit Lee at al found a similar inflammatory profile in both groups except for 
HSP 47[36] 
("#(#"
Pro-inflammatory cytokines as IL-1 and IL-8, pleiotropic cytokines as TNF-, IL-6 and IL-
13 and anti-inflammatory cytokines as IL-10 are all correlated to outcome in patients with 
ALI/ARDS[22, 37, 38]. 
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$#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!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In patients with ALI/ARDS studies have identified abnormal levels of tissue factor, factor 
VIIa, vonWillebrand factor, protein C, plasminogen activator inhibitor (PAI)-1, 2-plasmin 
inhibitor, thrombomodulin and fibrin[25, 39]. Increased plasma Protein C, elevated BALF 
PAI-1 and thrombomodulin are associated with worse outcome[24, 40].  
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In the classic separation between time periods in ALI/ARDS proliferation occurs after 7 to 14 
days. But in ARDS/ALI patients N-terminal pro-collagen peptide-III (N-PCP-III) a mediator 
of fibro-proliferative activity have been found already within 24 hours of the diagnosis, and 
increased N-PCP-III was associated with increased mortality[41–43]. 
Vascular endothelial growth factor (VEGF) has a role both to increase vascular permeability 
and as a mitogen for endothelial proliferation. Measurements of VEGF in BALF have been 
conflicting and the role of VEGF as a biomarker remains unclear. Low concentrations in 
BALF of ARDS patients may be caused by alveolar flooding of fluid[44]. 
Keratinocyte growth factor (KGF) and hepatocyte growth factor (HGF) are potent mitogens 
for type II alveolar epithelial cells and they are found to enhance motility, increase resistance 
to injury, surfactant production, decrease apoptosis and release of autocrine factors[45].  
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In the intact lung epithelia separates compartments and facilitates transport. One important 
mechanism is salt and water transport. Active Na+ transport and secondary active Cl- transport 
with consequent osmotic transport of water. There are two stages of damage to the blood-
alveolar barrier. In secondary acute mild to moderate lung injury there is dysfunction in the 
tissue, but in severe states of acute secondary lung injury the disruption of endothelium and 
epithelium requires repair with cellular growth to cover the basement membrane before 
regulation of ion transport can be restored, figure 1[46]. 
The endothelium is a semi-permeable barrier that lines the vasculature and regulates fluid and 
solute exchange between the blood and interstitial space. The surface of the endothelium is 
anti-thrombotic and anti-inflammatory. With the exposure to activated PMNs, platelets, 
chemokines and cytokines the endothelium shifts to a state of dysfunction. The endothelium 
expresses adhesion molecules and pro-coagulant factors (tissue factor, vonWillebrand Factor). 
IL-1 increases permeability by inducing TGF, increasing actin-stress fibers and disruption 
of gap junctions[47]. 
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Figure 1. Schematic diagram illustrating 3 potential alveolar environments that can be 
encountered in an injured lung. In regions where there is significant injury to the epithelium, 
epithelial repair will be needed before stimulation of ion transport can be achieved. In regions 
where normal epithelial function is preserved, pharmacological stimulation is possible. 
Finally, in regions where a proliferative response is present, there could be an intrinsic 
enhanced clearance[46]. Used with permission. 
 
TNF is proposed to contribute to endothelial apoptosis and edema formation by inducing 
reactive oxygen species production, destabilizing microtubules and thereby changes in the 
cytoskeleton with paracellular gap formations[48–52]. But Börjesson et al found TNF to be 
essential to protect the alveoli from flooding in a rodent intestinal IR model[53].  
Although there are early and profound changes in the lung vascular endothelium it seems that 
the prerequisite for alveolar edema is changes in function in the alveolar epithelium. In the 
normal lung the alveolar epithelium is impermeable to proteins. Fluid transport is regulated 
through apical epithelial sodium channels (ENaC). The fluid transport is driven by the basal 
adenosine triphosphate Sodium-Potassium pump (Na+-K+-ATPase) and up-regulation of the 
basal Na+-K+-ATPase can itself be sufficient to increase alveolar fluid clearance[54, 55]. The 
lung epithelial is resistant to injury and in models of hypoxemia, intestinal IR and intravenous 
or intra-alveolar infusion of endotoxin (LPS) the alveolar fluid clearance is increased by 
induction of apical ENaCs and basal Na+-K+-ATPase activity[54–56]. 
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The apical ENaCs are sensitive to many stimuli. ENaC activity is reduced by amiloride, -
blockers, IL-1, TGF and NO via soluble guanylyl cyclase and increased cGMP production. 
On the other hand -agonists, dopamine, glucocorticoids and reactive oxygen species are all 
shown to increase ENaC activity. TNF show conflicting results. Some studies concludes that 
TNF decrease ENaC activity and others have concluded that TNF increases alveolar fluid 
clearance when comparing to groups receiving TNF antibody[53, 57–59]. 
The lung epithelium maintains the ability to clear alveolar fluids in the absence of circulation. 
Even in the presence of moderate interstitial edema and moderately elevated left atrial 
pressure alveolar fluids are cleared by compensatory increased clearance. The lymphatic 
system and in some instances the pleural space can clear interstitial fluids. Nevertheless the 
lung circulation is the most important system for the clearance of excess fluids in the lung 
interstitium. When the pressure of the lung circulation and/or the lung interstitium increases 
further the clearance of alveolar fluids will be limited and insufficient[55]. Nevertheless in 
early secondary lung involvement, the inflammatory process is fully activated even prior to 
alveolar flooding. 
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The overall trauma of open AAA repair is a combination of general anesthesia with positive 
pressure ventilation, surgery (surgical dissection, bowel manipulation, intestinal hypothermia, 
mesenteric traction, aneurysm manipulation) and IR-injury. The procedure of elective open 
AAA repair is a surgical two hit model with an increased risk for development of remote 
injury in lungs, failure of kidneys and MOF. In addition patients with ruptured aneurysms 
suffer an initial period of variable hypotension and hypovolemic shock. In this group a more 
severe and sustained inflammatory response occurs and MOF is more frequent. The 
inflammatory response is characterized by an early activation of the cascades of coagulation, 
cytokines, eicosanoids and immune cells (PMNs)[60, 61].  
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The local release of cytokines at the site of surgery elicits a guided inflammatory response 
that in the end results in wound healing. Research on the quantity and the quality of the 
cytokine response has resulted in cytokine measurements being a parameter on prognosis. 
Roumen et al studied plasma cytokines in blunt trauma, elective and acute open aortic 
surgery, and found that IL-1, TNF- and IL-6 were increased in non survivors[62]. This 
underlines the importance of cytokines as markers of prognosis. 
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Open AAA repair induces a systemic inflammatory response with substantial release of 
cytokines in blood[28, 61, 63–71]. Our group has previously studied this response in the 
evaluation of open versus endovascular repair of abdominal aortic aneurysms[60]. IL-6 
correlates to the duration of aortic crossclamp and the development of SIRS and late 
complications[61, 70]. In addition to find overall outcome parameters a substantial effort has 
been done to find the main source of the lung response after aortic crossclamp. 
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During the procedure of open AAA repair the gastrointestinal tract are exposed to 
manipulation, hypothermia and hypoperfusion/ischemia. The hypoperfusion/ischemia may be 
facilitated by traction, bend on the mesenterium and absent blood flow of the inferior 
mesenteric artery.  
Mediators from the gut can be transported by blood or lymph to the systemic circulation. 
Blood samples from the portal or the inferior mesenteric vein have shown increased IL-6 
concentrations when compared to systemic values[63, 68]. Norwood et al compared IL-6 
from the portal vein with the femoral vein and systemic samples, and they found that IL-6 
values were highest in the portal vein[61]. But in experimental animal models with isolated 
gut IR-injury repeated experiments have shown that ligation of the thoracic duct lymph vessel 
to a great extent blunt the PMN recruitment in lungs and reduce vascular leak both in lung and 
intestine. The lymph in reperfusion contained high concentrations of TNF, IL-1 and IL-
10[72, 73]. It was further shown that lung tissue from animals exposed to IR-injury with 
ligated thoracic duct had lower levels of IL-1, IL-10 and VEGF[74].  
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In patients undergoing open AAA repair there are infiltration of PMNs in muscle tissue, 
endothelial activation and release of cytokines from the lower limb[75–77]. Concentrations 
from the femoral vein of IL-6 and IL-8 are found to be higher than the systemic 
concentration[78]. Norwood et al compared the release of activated PMNs, as measured by 
increased expression of integrins (CD11b), in the femoral and portal vein compared to the 
systemic circulation and found that activated PMNs mainly came from the lower limb[79]. In 
experimental animal models lymph collected from ischemic hind legs activates human 
pulmonary microvascular cells and human PMNs[80, 81].  
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Summing up the trauma of open AAA repair is sufficient to activate PMNs, lung alveolar 
endothelium inflammatory and coagulation cascades. The gut and the lower limbs send out 
their mediating signals via the lymph and thereby play up to the concert of organ crosstalk.  
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Hemodynamic and respiratory parameters available in the clinical setting fail to identify the 
inflammatory changes proceeding to clinical manifest ARF, ALI and ARDS.  
Both systemic and respiratory markers of inflammation have been studied to predict 
ALI/ARDS[34, 82, 83]. Donnely et al found BALF IL-8 to predict the development of 
ALI/ARDS[34]. In a clinical study on BALF from patients 2 to 6 hours after trauma 
Raymondos et al used IL-8 >200pg/ml to assign patients to a high-risk for ARDS group. Five 
out of eight patients in the high-risk group and only two out of sixteen in the low risk group 
developed ARDS. In addition the high-risk group had increase levels of alveolar IL-1, IL-
1ra, IL-6, IL-10 and TNF[35]. 
In a recent review of the biomarkers of ALI/ARDS the conclusion still have similarities with 
the state of previous decades. There are limited findings and no consensus. New markers are 
still not thoroughly evaluated. Proteomics and genomics are new fields that remain to be 
explored. Combination of biomarkers improves the predictive value, but there is still no “gold 
standard”[38]. A main problem not addressed by the review is the content of the samples and 
the methods used to validate existing biomarkers. 
ELF of the bronchi has been examined by BAL, direct aspiration, microsampling, and exhaled 
breath condensates. BAL and other bronchoscopic techniques have in common that they are 
invasive, may create lung injury[84–86], are based on single or intermittent samples and 
therefore have limited value as continuous and dynamic monitors of the ELF of the lung. The 
exhaled breath condensates technique is non-invasive and continuous, but is indirect and best 
suited for collection of non-volatile hydrophilic solutes and measurements do not correlate to 
BAL measurements[87–89]. 
The natural course from a sufficient stimulus to an inflammatory response, early tissue 
dysfunction and to manifest clinical lung symptoms is a dynamic process. Each time period of 
minutes, hours and days have their own characteristic presentation. The dynamics of 
inflammatory markers in the period before and in the beginning of the microscopic changes 
may reveal new knowledge with continuous sampling and greater time spatiality. 
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Microdialysis can continuously monitor metabolism and protein concentration with a 
potential of good time spatiality and may be a tool to improve the monitoring and 
prognostication of ARF, ALI and ARDS.  
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Aims of the study 
The overall aim of this thesis was to explore and evaluate a new method, bronchial 
microdialysis, for continuous sampling of the molecule composition, especially cytokines, in 
ELF in early lung involvement after distant IR-injury in both an experimental model and in 
the clinical setting. The specific aims were:  
 Evaluate bronchial microdialysis for continuous and dynamic monitoring of the time-to-
time changes in the composition of the ELF by lactate and FD-4 in a pig model. Evaluate 
arteriobronchial urea gradient as a correction factor. 
 To determine if bronchial microdialysis can identify the immediate inflammatory response 
in the bronchi as measured by IL-1, IL-8, and TNF and monitor the time-to-time 
changes of these cytokines during the first 4 h of reperfusion after intestinal ischemia in a 
pig model. 
 To investigate a broad spectrum of the bronchial and systemic inflammatory response in a 
time relation to the phases of open AAA repair and the immediate postoperative period by 
measuring 18 cytokines by microdialysis. 
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Methodological considerations
The methods have been discussed in detail in each manuscript. Only general comments of the 
methods will be given. 
	&  
The microdialysis technique as we know it today developed over decades[90]. It all started 
with dialysis sacs, push-pull cannulas and dialytrodes[91–93]. In 1974 Ungerstedt and Pycock 
established the first setup with “hollow fibers” in the brain[94]. The “hollow fiber” was 
intended to mimic a capillary blood vessel, figure 2.  
 
Figure 2. The Microdialysis Catheter mimics a blood capillary. Substances from the 
extracellular fluid of the tissue diffuse across the membrane of the catheter into the perfusion 
fluid inside the catheter. Used with permission. 
 
The method was refined and used in experimental animal models throughout the early 
eighties[95–98].  In the late eighties early nineties microdialysis was applied in humans[99–
101]. In the beginning microdialysis in humans was clinically used as a monitor of aerobe 
versus anaerobe metabolism (lactate-pyruvate ratio), cell injury (glycerol) in brain tissue after 
neurotrauma, neurosurgery and skin flaps after reconstructive surgery. New tissues have been 
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targeted. Examples are measurements of larger molecules as cytokines and concentration of 
medication in tissues of interest. A search on “microdialysis” on PubMed October 2012 
returns a number of 14425 publications (2709 on humans). 
Microdialysis probes were designed to monitor the extracellular compartment and to mimic 
capillaries, figure 2. The probe consists of two plastic tubes with one inside the other and an 
inlet and outlet part. At the end the microdialysis probe is formed as a concentric tube. The 
perfusion fluid enters the space between the inner tube and the outer dialysis membrane. This 
is where the “dialysis” takes place, i.e. the diffusion of molecules between the extra cellular 
fluid and the perfusion fluid. The diffusion passively follows the concentration gradient 
(Fick’s first law of diffusion). Perfusion fluid is pumped into the inlet and is collected at the 
end of the outlet line, figure 3. Though microdialysis is most often used to measure molecule 
concentration in different tissues the method can also be used a substance delivery system 
with reversed concentration gradients. 
 
Figure 3. Microdialysis catheter with pump and collection vial connected. Schematic 
presentation of the semipermeable membrane. Used with permission. 
 
Today there are a wide range of probes for research and also clinical application. The physical 
appearance is adjusted to the application with difference in length of the probe and the 
semipermeable membrane (1 to 30 mm). The semi-permeable membrane material 
characteristics and pore-size (6-100kDa) vary to determine which molecules that can be 
collected. 
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Microdialysis was traditionally used in brain and skin flaps after reconstructive surgery. 
Today microdialysis is used in most solid organs, glands, in the intestinal lumen and in 
tumors. Microdialysis is applied as a monitor of metabolism, sampling of proteins, 
pharmacodynamic/pharmacokinetic studies and as a drug delivery unit. 
When a probe is implanted into solid tissue bleeding and inflammation ensue and a washout 
period is necessary. A probe can function for a long time, up to 30 days, and the membrane is 
resistant to bio-fouling[102]. But in solid tissue a foreign body reaction can lead up to the 
build of a capsule that alter the local milieu shown to decrease the recovery of IL-6 already 
after 3 days[103]. To my knowledge this challenge is not applicable to luminal microdialysis. 
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In two fluid compartments with different composition separated by a semipermeable 
membrane the molecules that can diffuse over the membrane will equilibrate over time. With 
microdialysis fluid on the inside of the membrane is exchanged regularly. The speed of 
exchange is dependent on the microdialysis pump flow, usually 0.1 to 5 μl/min.  
The ability to measure the molecule of interest is called the extraction efficiency, formula 1. 
If Cin is zero the formula can be simplified to Cout/Cmedium. This factor is called the relative 
recovery, which is used to communicate the overall performance of the microdialysis method. 
The absorption of the molecule is a total description of the mass transport of the molecule in 
and out of the microdialysis catheter. This is used to calibrate the system. The mass transport 
is composed of sequential properties by the molecule and the external medium (fluid/tissue). 
The components are mass transport of the molecule through the external medium 
(fluid/tissue), the semipermeable membrane of the probe and properties of the 
perfusate/dialysate.  
The resistance (R) is related to the EE as shown in formula 2[104]. 
The resistance of the perfusate/dialysate (Rd) is dependent upon the length of the lumen and 
the diffusion constant in the perfusate/dialysate. The resistance of the membrane (Rm) is 
dependent of the geometry with inner and outer diameter, outer diameter of the inner cannula, 
length of the membrane, volume fractions of these three transport regions and the molecule 
Formula 1. Extraction efficiency (EE).  
Cout and Cin are the concentrations of the molecule in the dialysate and perfusate. Cmedium 
is the absolute concentration in the surroundings of the membrane (tissue/fluid). 
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diffusion constant. The resistance in the external medium (tissue/fluid) (Rv) is a function of 
diffusion and kinetic processes in the external medium (tissue/fluid)[104].  
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The microdialysis catheter must be calibrated before one can conclude about the absolute 
concentrations of a molecule in the surroundings of the microdialysis membrane. There are 
several techniques to find EE of the microdialysis catheter. 
With the no-net-flux method the microdialysis catheter is perfused with several known 
concentrations of the molecule of interest and a regression line is created between the 
increase/decrease in concentration of the molecule in the dialysate and the concentration of 
the molecule in the perfusate. At the no-net-flux point the EE is similar to the constant in the 
regression equation. The method assume steady state during the calibration[99]. 
The zero-flow technique measures the recovered concentration of the molecule at different 
flow rates and extrapolates the results to zero-flow, and thereby the EE of the microdialysis 
catheter[105]. 
Internal reference is also used. A known concentration of the molecule is added to the 
perfusate. The microdialysis membrane is immersed in a medium without the molecule of 
interest. The decrease in concentration of the molecule in the dialysate is used to calculate the 
EE. 
In vitro calibration, both of quiescent and stirred media have been repeatedly validated. The 
limitation of the method is that the resistance of the medium (tissue/fluid) in vivo is not 
included. In vitro calibration will generally overestimated the EE.  
The above-mentioned methods are time-consuming. Endogenous compounds have been 
evaluated to find a calibration method that can be carried out during the experiment. Urea is a 
small molecule that moves fast and freely between compartments and immediately 
equilibrates in the tissue water space. Different applications of the medium/dialysate ratio of 
Formula 2. Mass transport. 
Qd is the perfusate flowrate. The mass transport in the perfusate/dialysate (Rd), 
the microdialysis membrane (Rm) and the external medium (tissue/fluid) (Rv) 
is to a great extent dependent on the molecules diffusional capacity. 
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urea have been proposed. Strindberg and Lönnroth found urea as an endogenous reference to 
correlate significantly with internal reference method and no-net-flux calibration[106]. 
The “real” concentration is not easy to find and researchers regularly experience the fact that 
results from different studies are not directly comparable even if the method used was the 
same. Even though a great effort has been done to find good calibration methods this lead up 
to that analysis of data relates to the relative relation between data values, and that 
conclusions relate to change more than the “real” concentrations. 
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The application of bronchial microdialysis in pigs and humans were not previously described. 
The feasibility of the method is an important part of this thesis contribution to new knowledge 
on possible methods to monitor the composition of the ELF. 
 
Figure 4. The application of bronchial 
microdialysis. 
 
In the animal studies (Paper I and II) we 
used custom made probes based on the 
CMA20. The membrane was standard 
with a diameter of 0.5 mm and a length 
off 10 mm with 100 kDa cut-off. The 
shaft was lengthened to 90 mm and inlet 
and outlet were 435 mm. The catheter 
was placed under guidance of fiberoptic 
bronchoscopy, figure 4. We also created 
our own design for intra-arterial 
placement of these custom made 
catheters through a venous catheter with 
a luer-lock connection, figure 5. 
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In the human study (Paper III) a catheter that was approved for use in humans had to be used 
to avoid material compatibility issues. CMA used their CMA71 catheter for human 
application as a template. The membrane was standard with a diameter of 0.5 mm and a 
length of 10 mm with 100 kDa cut-off. The shaft was lengthened to 90 mm and inlet and 
outlet were 600 mm. The catheter was placed under direct laryngoscopy and wedged. The 
position was confirmed by fiberoptic bronchoscopy. 
 
Figure 5. Custom made microdialysis catheter modified with luer-lock connector for 
intravenous application 
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The analysis of urea, lactate and glycerol was done on a miniature clinical analyzer (CMA 
600) “bed-side” with the results within 5 to 10 minutes after each sampling period. Lactate 
and glycerol reacts with the reagent and produces hydrogen peroxide in amounts reflecting 
lactate and glycerol concentrations. Hydrogen peroxide catalyzes the reaction forming a red-
violet quinoneimine. The rate of formation is measured photometrical at 546 nm and is 
proportional to the concentration of lactate and glycerol. 
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Urea is hydrolyzed by urease to ammonium and carbon dioxide. The ammonium ions react 
with 2-oxygoutarate in the presence of glutamate dehydrogenase and nicotinamide adenine 
dinucleotide (NADH) (reducing agent - electron donor) to form glutamate and NAD+ 
(oxidizing agent – accepts electrons). The utilization of NADH is measured photometrical at 
365 nm and is proportional to the urea concentration. 
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Figure 6. Schematic presentation of a sandwich-
based Bio-Plex assay workflow. Used with 
permission. 
The Luminex XY platform with xMAP technology is 
based on flow cytometry technology. Microplates 
with 96 wells are used. With this technology sample 
volumes down to 15 μl can be used to quantify 
several cytokines of interest[107]. In short the sample 
is added to a solution of a defined selection of colored 
capture beads. Thereafter the mix is incubated with 
biotinylated detection antibody. In the end 
streptavidin-PE reporter dye is incubated. The beads 
are re-suspended and each microsphere is analyzed 
separately in a tube by a classification laser that reads 
the color of the bead and simultaneously a report laser 
read the intensity of reporter dye. 
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Urea (60 Da) is a small molecule which rapidly equilibrates in extracellular compartments 
included the ELF of the lung[108]. Urea has been repeatedly used as an endogenous marker in 
equilibrium to calculate the ELF amount in BAL and to calibrate microdialysis samples from 
various tissues[99, 109–112]. 
In bronchial microdialysis there is constant movement within the respiration-cycle. The 
microdialysis catheter was fixed proximally in the trachea and we postulated that the part of 
the microdialysis membrane in contact with the ELF would vary during inspiration and 
expiration, figure 7. The arteriobronchial urea-gradient as presented by Rennard was used to 
Step One: 
Dispense capture beads 
Wash plate 2 times
Step Four:
Add streptavidin-PE reporter dye
Incubate
Wash plate 3 times
Step Two: 
Add samples
Incubate
Wash plate 3 times
Step Five:
Resuspend beads
Perform fluorescent sorting
Analyze data
Step Three:
Add biotinylated detection antibody
Incubate
Wash plate 3 times
Classiﬁcation laser
   
Reporter laser
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estimate the part of the microdialysis membrane that was in contact with the ELF in Paper I 
and II[109].  
 
Figure 7. Schematic presentation of bronchial microdialysis during the respiratory cycle. The 
microdialysis membrane will move within the bronchi caused by the inflation and deflation of 
the lung.  
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Generally permeability experiments in hollow organs can either be performed by 
administration of the marker molecule to the lumen of the hollow organ with measurements in 
plasma or urine, or the marker molecule can be administered to blood with a standardized 
sampling procedure within the hollow organ. Tight junctions mainly regulate permeability by 
the paracellular route. Hydrophilic marker molecules with a cross sectional diameter of 1-3 
nanometer most likely use the paracellular route caused by breaks in the tight junctions 
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induced amongst other molecules by cytokines[113–116]. Fluorescein isothiocyanate dextran 
4000 Da (FD-4) matches these criteria.  
In Paper I and II, we estimated the permeability from blood to the terminal bronchi as 
measured by bronchial microdialysis. We used an intravenous infusion of FD-4 and clearance 
was measured with a fluorescence spectrophotometer. In Paper II the concentration of FD-4 
was measured in baseline and during 4 hours of intestinal reperfusion after 2 hours 
crossclamp of the superior mesenteric artery. 
In Paper II we measured intestinal permeability changes. A microdialysis catheter for 
measuring FD-4 was introduced into a jejunal loop 60 to 90 cm distal of the ligament of 
Treitz. The loop was closed at each end with ligatures and flushed with 50 mL Ringer acetate 
until the fluid was clear by visual control. Detection of FD-4 in the microdialysate was used 
as a marker of alterations in intestinal permeability. 
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In Paper II a lung specimen was collected from the right diaphragmatic lobe through an 
anterior transdiaphragmatic access from the abdominal cavity. 
Hematoxylin-eosin stained sections were examined for alveolar hemorrhage, fibrin 
deposition, thickening of alveolar septa, vascular congestion, and neutrophil granulocytes in 
10 random areas at 10X magnification in each section. Neutrophil granulocytes were counted, 
and the other findings were scored on a semi-quantitative scale (0, no injury; 1, mild injury; 2, 
moderate injury; and 4, severe injury), modified from Douzinas et al. [117]. The M30 
Cytodeath (Roche, Basel, Switzerland) antibody recognizes a specific caspase cleavage site 
within cytokeratin 18 present in early apoptosis. Apoptotic cells were counted in 10 random 
areas at 10X magnification in each section. Areas with bronchial tissue were excluded in 
histological examinations. 
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Young pigs, weighing 22-31 kg, were used in Paper I and II. Pigs are widely used in 
experimental circulatory research. Pigs like humans have relatively low concentrations of 
xanthine oxidase with the consequence that reperfusion injury and no-reflow phenomenon 
may be less pronounced than in rodents and cats[118, 119]. 
Intestinal ischemia-reperfusion is a well-known model of secondary lung injury. The PubMed 
search, (("Lung"[Mesh]) AND "Intestines"[Mesh]) AND ("Ischemia"[Mesh] OR 
"Reperfusion Injury"[Mesh]), returned 179 publications October 2012. 
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Inhalational anesthesia with volatile anesthetics increase concentration of some bronchial 
inflammatory mediators and decrease others[120–123]. To avoid lung effects of volatile 
anesthetics, fentanyl and ketamine were used. 
To avoid ventilation induced lung injury the ventilator strategy was harmonized with the 
current research on optimal ventilator strategy in humans[30, 31]. To avoid ventilation-
induced lung injury, peak inspiratory pressures was less than 20 cm H2O, positive end-
expiratory pressure was set at 7 cm H2O, and tidal volumes were 6 to 8 mL/kg. Fluid balance 
was obtained by an intravenous infusion of heated (37°C) crystalloid fluids throughout the 
experiments. Rectal temperature was maintained within the normal range (37°C-39.6°C) by a 
heating mattress and wrappings[124]. 
The trauma of surgery was minimized by the assistance of experienced surgeons within our 
own group. 
In Paper III the method of bronchial microdialysis was evaluated in open AAA repair patients. 
Both the feasibility and the ability to monitor the inflammatory response were controlled. 
open AAA repair induce a systematic inflammatory response bi IR. The IR-injury of both the 
gut and the lower limbs is sufficient to induce remote organ failure of the lung and other 
organs[28, 61, 63–71].   
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In Paper I parametric test-statistics was used. Evaluation of bronchial microdialysis and urea-
corrected bronchial microdialysis as an approximation of arterial microdialysis were 
presented as accuracy. To evaluate improvement in precision by urea-correction, the 
coefficient of variation was used. Coefficient of variation = Standard deviation/Mean·100. A 
significant reduction in the coefficient of variation by use of urea-correction was used to 
confirm the justification of the method. 
In our papers there was a limited number of observations for each parameter and it was open 
to discussion whether the criteria for parametric testing always was present. Therefore we 
used non-parametric testing in Paper II and III. To assess changes within the groups over 
time, the Friedman test was used. Wilcoxon signed rank test was used to compare different 
time points within groups, and in Paper III the Bonferroni correction for multiple testing was 
used to avoid false positive results. Mann-Whitney U test was used to compare groups. Fisher 
exact test was performed on binomial data. The Spearman’s  was used to identify 
correlations. Spearman’s  uses ranks to calculate the correlation coefficient.  
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Summary of results 

(!"" !!!"&
&  
The aim of the first paper was to evaluate bronchial microdialysis as a possible method for 
continuous and dynamic monitoring of the time-to-time changes in the composition of the 
ELF. Lactate and FD-4 were administered intravenously by continuous infusion to maintain 
two levels of steady state. Arteriobronchial urea-gradient was used as a correction factor to 
calculate the absolute concentration of lactate and FD-4 in the bronchial ELF. The 
arteriobronchial lactate gradient was 1.2 ± 0.1 and FD-4 gradient was 4.0 ± 1.2. 
Arterial and bronchial concentrations of lactate and FD-4 showed similar relative 
concentration changes, figure 8 and 9. Correction of the bronchial lactate concentrations with 
the arteriobronchial urea-gradient improved the accuracy and the precision of the 
measurements. For FD-4 there were a trend to improvement in accuracy and precision.  
We concluded that bronchial microdialysis was an applicable continuous monitor of the 
dynamic changes in the composition of the ELF. The absolute concentrations of the measured 
molecules could be estimated with acceptable precision using a correction by the 
arteriobronchial urea gradient. 
 
Figure 8. Overview of the lactate infusion 
with two steady states. Data are presented as 
mean lactate values by arterial microdialysis 
(solid line) with mean values in steady state 
(filled triangles), bronchial microdialysis 
(long dash line) with mean values in steady 
state (filled circles) and ureacorrected 
bronchial microdialysis (dash-dot line) with 
mean values in steady state (open circles). 
The circles and the triangles represent the time where the microdialysis vials were exchanged 
for the steady state samples. The gray area is a graphical presentation of the intravenous 
lactate infusion. During the low steady state the infusion of sodium lactate was gradually 
increased to maintain an arterial blood lactate of ~5 mmol/L. During the high steady state the 
infusion of sodium lactate was increased to maintain an arterial blood lactate of ~10 mmol/L.  
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Figure 9. Overview of the fluorescein 
isothiocyanate dextran 4000 Da (FD-4) 
infusion with two steady states. Data are 
presented as mean FD-4 values by arterial 
microdialysis (solid line) with mean values in 
steady state (filled triangles), bronchial 
microdialysis (long dash line) with mean 
values in steady state (filled circles) and 
ureacorrected bronchial microdialysis (dash-dot line) with mean values in steady state (open 
circles). The circles and the triangles represent the time where the microdialysis vials were 
exchanged for the steady state samples. The gray area is a graphical presentation of the 
intravenous FD-4 infusion. The infusion was started with an intravenous bolus of 10 μg/kg 
over 10 minutes. In the low steady state an infusion of FD-4 at 5 μg/kg/hour was maintained. 
After the low steady state a new intravenous FD-4 bolus of 10 μg/kg over 10 minutes was 
infused. In the high steady state an infusion of FD-4 at 10 μg/kg/hour was maintained. 
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At the time there was no continuous monitor to measure cytokines in the bronchial ELF or the 
intestine. The aim of the study was to evaluate bronchial microdialysis as a method to 
continuous monitor early lung cytokine response (IL-1, TNF and IL-8) and altered blood-
alveolar permeability (FD-4) secondary to intestinal IR in pigs. We also measured the 
cytokine response and permeability changes in the intestine by luminal microdialysis. 
Intestinal IR-injury was induced by cross-clamp of the superior mesenteric artery for 120 min 
followed by 240 min of reperfusion. We hypothesized that microdialysis could identify the 
immediate inflammatory response and permeability changes in the bronchi and the intestines 
as measured by IL-1, TNF, IL-8 and FD-4, and monitor the time-to-time changes of these 
cytokines during the first 4 hours of reperfusion after intestinal ischemia. Sham-operated pigs 
served as controls. 
In the ischemia group during reperfusion, mean pulmonary artery pressure and pulmonary 
vascular resistance increased to values higher than reference values for conscious pigs. 
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During reperfusion the ischemia group presented individual differences in the concentrations 
of bronchial IL-8 and IL-1. Bronchial IL-8 and IL-1 in the ischemia group increased during 
the reperfusion phase as compared with baseline, and there were increase between different 
time points and between the ischemia group and the control group. Already within 1 hour of 
reperfusion bronchial epithelial lining fluid levels of both IL-8 and IL-1 increased. Most 
bronchial TNF samples were below the limit of detection. Luminal intestinal IL-8 increased 
in the ischemia group. The measured levels of intestinal IL-1 were low, and there were no 
changes during reperfusion compared with baseline. Intestinal TNF- was below the limit of 
detection in all samples in both groups. Cytokine levels obtained by arterial microdialysis 
were mostly below the limit of detection and were not suitable for statistical analysis. All 
plasma samples on IL-1, TNF and IL-8 in all animals were below the limit of detection. 
During reperfusion, the concentration of IL-6 in pulmonary serum increased in the ischemia 
group compared to the control group. In this study we had a high limit of detection for TNF 
and this must be considered when interpreting the data. 
Intestinal luminal lactate and FD-4 was increased during reperfusion.  Bronchial lactate and 
FD-4 were the same in both groups. The baseline FD-4 concentration in the bronchi was 
approximately one half of the arterial concentration; and in the intestinal lumen, the 
concentration was less than one tenth of the arterial concentration. 
There was no histological pathology as sign of diffuse alveolar damage in hematoxylin-
eosin/stained sections or number of apoptotic cells as indicated by immunohistochemistry. 
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The aim of this study was to investigate a broad spectrum of the bronchial and systemic 
inflammatory response in a time relation to the phases of open AAA repair and the immediate 
postoperative period by measuring 18 cytokines by microdialysis. Sixteen consecutive 
patients scheduled for open AAA repair were included. The patients served as their own 
controls. Cytokines were measured in bronchial ELF and venous blood by microdialysis 
during open AAA repair and the first 120 minutes of reperfusion. Serum samples were 
collected the day of surgery and the three following days. Three patients were admitted to the 
critical care unit directly after surgery and had organ failure(s) that persisted more than 24 
hours (Organ Failure-group).  
Eight out of eighteen bronchial cytokines measured by microdialysis presented an overall 
change in relation to the trauma. IL-5, IL-6, IL-13, and GM-CSF had their peak during 
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reperfusion, IL-2, IL-4 and TNF- showed an overall change with their highest concentration 
during reperfusion and IL-7 was reduced during ischemia and reperfusion. Bronchial cytokine 
concentrations by microdialysis in the Organ Failure-group were statistically different from 
the Non Organ Failure-group in seventeen out of eighteen cytokines (IL-1, IL-2, IL-4, IL-5, 
IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-CSF, IFN-, MCP-1, MIP-1, MIP-1 
and TNF-). Bronchial cytokines correlated to aortic aneurysm diameter, s-creatinine, GFR, 
previous coronary intervention, kidney disease, statin use, duration of cross-clamping, 
duration of surgery, duration of anesthesia, critical care days, volume of erythrocyte 
transfusion and MPAP. 
Venous IL-2, IL-5, IL-7, IL-13, G-CSF, IFN- measured by microdialysis were below limit of 
quantification in more than half of the samples. Further analysis was omitted for these six 
cytokines. Eleven out of the remaining twelve cytokines presented an overall change in 
relation to the trauma. IL-1, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), IL-17, MCP-1, MIP-1, 
MIP-1 and TNF- had a peak during reperfusion and in addition TNF-, MIP-1 and MIP-
1 increased already during ischemia. Venous cytokine concentrations by microdialysis in the 
Organ Failure-group were statistically different from the Non Organ Failure-group in four out 
of twelve cytokines (IL-4, IL-17, MCP-1 and MIP-1). Venous cytokines as measured by 
microdialysis correlated to age, aortic aneurysm diameter, kidney disease, acetylsalicylic acid 
use, smoking status, duration of cross-clamping, duration of surgery, duration of anesthesia, 
volume of erythrocyte transfusion, volume of other fluids, MPAP, lung compliance, 
temperature, duration of stay, and number of organ failures. 
Serum IL-2, IL-17 and GM-CSF were below limit of quantification in more than half of the 
samples. Further analysis was omitted for these three cytokines. Fifteen out of the remaining 
fifteen cytokines presented an overall change in relation to the trauma. IL-1, IL-4, IL-5, IL-
7, IL-12 (p70), IL-13, IFN- and TNF- had their highest concentration in the sample 
collected immediately after induction of anesthesia, IL-8, IL-10, G-CSF, MCP-1, MIP-1 had 
their highest concentration during reperfusion, IL-6 peaked on the morning of the 1st 
postoperative day and MIP-1 had the lowest concentration on the first postoperative day. 
Serum cytokine concentrations in the Organ Failure-group were statistically different from the 
Non Organ Failure-group in seven out of fifteen cytokines (IL-1, IL-5, IL-8, GM-CSF, MIP-
1, MIP-1and TNF-). Serum cytokines correlated to acetylsalicylic acid use and MAP.  
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General discussion 
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Studies on bronchial epithelial lining fluid have been limited by the available methods. BAL 
has been judged being the “gold standard”. But the method has defined weaknesses. BAL 
allows only a few intermittent samples in each individual caused by the invasiveness and the 
side effects of the procedure. The method itself elicits pulmonary hypertension with right 
ventricle distension, arterial deoxygenation and an acute phase response[85, 86, 125]. 
Although regarded as a safe procedure there is a considerable frequency of complications of 3 
to 10 %[126, 127]. The one major challenge with BAL is to determine the exact concentration 
of the molecules of interest. The method is based on repeated instillation of fluids within a 
bronchus, washout of bronchial fluids and thereafter collection of the alveolar fluids. To 
approximate the absolute concentration in the ELF a correction factor is needed to estimate 
the proportion between instilled fluid and ELF within the collected sample. Urea is frequently 
used as a correction factor, but there is still a controversy on the reliability. Instillation 
volume, dwell time, injured versus normal lung and other individual applications of the 
technique influence the composition of the collected sample[128–131]. 
Other techniques for collecting ELF existed at the time for start of this project. Exhaled breath 
condensates are noninvasive, but compromised by uncertainties concerning the sources of the 
droplets and by the extreme and variable dilution of ELF droplets with condensed water vapor 
(approximately 20,000-fold) and exhaled breath condensates measurement results are not 
comparable to BAL[87–89]. Bronchial microsampling and direct aspiration are invasive and 
only allows intermittent sampling. The diameter of the equipment limits the possibility to get 
samples from the smallest airways[132, 133]. 
The overall aim of this thesis was to explore and evaluate the molecular composition, 
especially cytokines, in ELF in early lung involvement after distant IR-injury in both an 
experimental model and in the clinical setting. None of the existing techniques were suitable 
for this and we concluded that we were in need of a new method for continuous sampling 
from bronchial ELF. 
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Microdialysis was originally designed to be a capillary within cellular organs and tissues and 
thereby collect molecules from the immediate surroundings[101]. The technique was later 
applied to the lumen of intestines. In our group we had experience with microdialysis applied 
in the intestinal lumen[134–136]. After a Pubmed search we found that bronchial 
microdialysis had been used in one rodent study[137]. New challenges presented with the idea 
of using microdialysis in the lungs within the bronchi of large animals and humans. As 
opposed to soft intestines the bronchi are stiff lumens held open by cartilage rings and 
connective tissue. 
The bronchial tree has been well characterized through morphometrical studies and terminal 
bronchi and bronchioles have a diameter of 0.6-1.5 mm[138, 139]. The diameter of the 
microdialysis membrane of 0.5-0.6 mm allows positioning within a terminal bronchus or a 
bronchiole in humans.  
We started pilot studies on bronchial application of microdialysis in pigs and the method as 
presented in Paper I and II was designed, figure 4. In the pig model we succeeded with a 
fiberoptic guided technique with visual control during insertion of the microdialysis catheters. 
With a tracheostomy the angle and distance to the distal airway was kept to a minimum. We 
tried to verify the position of a bronchial microdialysis catheter perfused with a radio-contrast 
agent by DynaCT, but we were not able to detect the tip of the catheter in vivo probably 
caused by the minimal diameter of the microdialysis catheter. We also tested perfusion of the 
microdialysis catheter with methylene blue and post mortem dissection, but the exact position 
of the bronchial microdialysis catheter was not determinable.  This is a limitation of the 
method at present. An in vivo technique to confirm the exact position within the bronchial 
tree would improve the reliability of the method. 
In Paper III, the human study, we had to use microdialysis catheters that were approved for 
use in humans with a different material in the tubing. Patients were endotracheally intubated 
via the oral route. In pilot studies in pigs we were able to insert the catheter through the 
bronchial blocker port in the Arndt Multiport adapter (an adapter placed on the endotracheal 
tube with ports for fiberoptic bronchoscopy, bronchial blocker and connection to ventilator) 
and wedged in a terminal bronchus. But after attempts in patients we concluded that this was 
not possible and the method was totally redesigned. The bronchial microdialysis catheter was 
prepared before the experiment by placement within a 14 G suction catheter and the 
biocompatible sterile outer sheath were manually cut to fit this application, see figure 10. Our 
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bronchial microdialysis catheter was introduced under direct laryngoscopy until it wedged and 
thereafter the patient was endotracheally intubated. The position of the catheter was 
confirmed by fiberoptic bronchoscopy with a thin bronchoscope (outer diameter 2.1 to 2.3 
mm) without working channel. The ideal image was to see the microdialysis catheter 
disappear within a terminal bronchus.  
Figure 10. The bronchial microdialysis catheter prepared for insertion in patients. 
 
 
 
In pilot studies and Paper I, II and III about 60 bronchial microdialysis catheters have been 
placed in pigs and humans. The method is feasible and appears safe with no observed major 
complications as visible bleeding, deoxygenation or other respiratory complications. 
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The bronchi move distally during inspiration and proximally during expiration. With a 
microdialysis catheter fixated proximally in the trachea the membranous area in contact with 
the epithelial lining fluid will vary, figure 7. Rennard et al and Eisenberg and Eckoff had 
previously presented urea as an endogenous factor with equal concentration and equilibration 
between body compartments[109, 110]. Strindberg evaluated urea applicable and as good as 
other calibration techniques for in vivo calibration of microdialysis catheters[106]. In Paper I 
we addressed the issue of variable area of microdialysis membrane in contact with the thin 
film of bronchial ELF. To produce standardized conditions a lactate and FD-4 clamp at two 
levels of concentration in blood were administered by continuous intravenous infusion. Urea 
was measured and used as a correction factor. Urea-correction increased accuracy and 
reduced coefficient of variation for lactate and a trend to improvement for FD-4 that did not 
Microdialysis pump
14G Suction catheter
Membrane 10mm
Vial
Protection sheath
cut to fit
Inlet
Outlet
 48 
reach significance. The FD-4 results must be judged in light of technical challenges as 
described in Paper I1. Based on the improved accuracy and reduced coefficient of variation we 
chose urea as an in vivo correction factor of the microdialysis membrane function within the 
bronchi in Paper I and II. One weakness in our application in Paper I and II was that we did 
not add urea to the perfusion fluid in microdialysis catheters. This may have influenced results 
by a depletion of urea in the immediate surroundings of the microdialysis catheter within the 
bronchus. In circulating blood it is reasonable to assume that the issue with urea depletion 
could be neglected. As a consequence the corrected bronchial concentrations of molecules 
could be overestimated. In Paper III urea-correction was omitted because a number of 
measured readings on the Luminex were above the standard curves and the exact 
concentrations measured were not possible to estimate. This was further complicated since the 
measurements had to be separated on two microplates with separate standard curves. With the 
uncertainty of the real concentrations of the high readings we decided to omit the urea-
correction in Paper III. Regardless of this Paper III showed an increase in bronchial cytokines 
in accordance with our findings in Paper II. 
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Inflammation increases the permeability of the endothelium both in quantity and in quality. 
With severe inflammation the disruption of gap junctions allows fluids, ions and proteins 
increase access to lung interstitium. Inflammation also increases the permeability of alveolar 
epithelium. But the alveolar epithelium has a great capacity for compensatory increase in 
transport of fluids and ions by increased activity in apical ENaCs driven by the basal Na+-
K+-ATPase. When it comes to the alveolar permeability to larger molecules the knowledge is 
more limited. Caused by the complexity of the blood-bronchial barrier, with three different 
functional units (endothelium, interstitium with lymph and epithelium) all sensitive to 
external stimuli, most studies on molecular transport have been conducted in cell-cultures and 
isolated organs. Molecule-size dependent paracellular and transcellular transport have been 
verified and FD-4 is found to be a marker of paracellular transport[113, 114]. In Paper I we 
                                                
1 Pilot in vitro studies of low volume FD-4 samples were conducted with wells containing 15 μl, 25 μl 
and 40 μl. With wells containing 15 μl there was a great variance and by visual inspection we saw that 
this small volume did not cover the bottom of the well. Wells containing 25 μl and 40 μl gave similar 
results and variance. During analysis of the last fluorescein isothiocyanate results from the in vivo 
experiment, we registered that wells with higher concentrations of FD-4 increased the registered result 
of neighboring wells with lower concentration of FD-4. We concluded that this maybe was caused by 
the use of microplates with translucent wells and in paper II we used microplates with white opaque 
wells. 
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found that there was a blood-bronchial gradient of about 4:1 for FD-4 in anesthetized positive 
pressure ventilated pigs. In Paper II we found no difference in the blood-bronchial FD-4 
gradient in pigs after intestinal IR-injury and sham-operated controls. This finding indicated 
that in our pig-model of intestinal IR-injury there were no disruptions of the tight junctions in 
alveolar epithelium. This was in accordance with the histological findings in Paper II with no 
sign of diffuse alveolar damage2. 
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In Paper I we examined bronchial microdialysis under standardized conditions with a lactate 
and a FD-4 clamp by intravenous infusion. We evaluated the methods accuracy and precision. 
We concluded that bronchial microdialysis could be an applicable method to continuously 
measure the concentration of molecules in the bronchial ELF. 
The term accuracy demands knowledge of a true value. The term is well accepted in the 
validating literature, but a more suitable term would have been agreement. Even though the 
ABL700 (Radiometer, Copenhagen, Denmark) is considered the best analyzer available (the 
gold standard) we have no evidence that we measure the true value with certainty. In addition 
lactate concentrations in plasma is higher than in erythrocytes and this introduce uncertainty 
when comparing blood to microdialysate[140]. 
Blood lactate concentrations were measured on the ABL700 (Radiometer, Copenhagen, 
Denmark). The concentration of the microdialysate in arterial microdialysis and bronchial 
microdialysis was measured on the CMA600 (CMA Microdialysis AB, Stockholm, Sweden). 
We found the CMA600:ABL700 ratio for lactate concentrations to be 1.13:1. 
In Paper I we present our findings as accuracy and coefficient of variation (precision). In 
Paper II and III we have based our conclusions on the precision more than the accuracy or 
agreement. The ability to measure molecules continuously and detect substantial changes 
between several time-intervals with good time-resolution is the strength of the method and the 
status of the methods validity at present.  
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In Paper II and III we found increased concentrations of bronchial cytokines in response to 
IR-injury. The cytokine concentrations were higher in bronchi than in blood. Our data support 
                                                
2 We had also performed biopsies for electron microscopy of the alveolar cells and their tight 
junctions, but caused by capacity problems at the electron microscopy laboratory the sections were not 
produced. 
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that cytokine production is compartmentalized, with local production (alveolar epithelial cells 
and alveolar macrophages) of the majority of cytokines found in the bronchi. 
IR-injury in both an animal model of intestinal IR and in open AAA repair with 
crossclamping of the abdominal aorta gave an immediate response. In Paper II we found an 
increased concentration of IL-1 and IL-8 already within the first 60 minutes of reperfusion. 
In Paper III we found decreased IL-7 during ischemia, increased IL-6, IL-13 and GM-CSF 
within the first 60 minutes of reperfusion and an overall change in TNF. In Paper III we 
additionally found a difference in the concentration of 17 out of 18 cytokines in patients with 
perioperative organ failure group when compared to patients without perioperative organ 
failure. None of the included individuals fulfilled criteria of ALI or ARDS. We found that 
production of bronchial cytokines came early. We found a measureable inflammatory 
response within minutes and up to an hour after the distant IR-injury. In summary Paper II 
and III found concentration changes in well-defined and important cytokines in the early 
inflammatory response (IL-1, IL-6, IL-8 and TNF). Bronchial cytokines seem to have 
interest beyond the scope of lung organ failure as defined by ARF, ALI and ARDS. Our 
findings open up a possible research area of lung inflammatory response in immediate organ 
crosstalk when the organism is exposed to trauma; in our project the trauma was IR-injury.  
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A special quality with microdialysis is continuous sampling. With continuous sampling, the 
measured concentration is the mean area under the curve for the time-interval when the 
sample was collected. The time-resolution is determined by the time between the exchanges 
of the collection vials. In studies on cytokines a volume of 15 μl is sufficient allowing a time 
resolution of about 15 minutes[107]. The concentration measured in each individual sample is 
the actual area under the curve for the measurement period. In Paper III we had designed the 
study with microdialysis and intermittent serum samples with sample time-point and time-
intervals according to previously conducted studies on open AAA repair patients[28, 62]. The 
first serum sample was drawn immediately after anesthesia induction. When comparing 
cytokines in samples from venous microdialysis and serum samples we were surprised with 
the difference in concentration-profile of the cytokines measured within the same 
compartment. To our knowledge the timing of the first serum sample have not been 
previously addressed. With a literature-search we found that some studies used samples from 
the day before surgery and some after anesthesia induction[28, 62, 64, 65]. Venous 
microdialysis was established immediately after anesthesia induction with a median sample-
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period of 2 hours and 5 minutes and the cytokine concentrations were low when compared to 
ischemia and reperfusion periods. In serum samples we found high cytokine concentrations in 
our after-anesthesia-induction-samples when compared to ischemia- and reperfusion-samples. 
In Paper II the concentrations in all intermittent samples from blood were generally below 
limit of quantification, maybe caused by lower sensitivity of the analysis method. The finding 
in Paper III is not conclusive, but the occurrence of the phenomenon puts a question mark 
behind previously conducted projects and calls for studies to clarify the issue. 
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Conclusion - answer to the aims 
Aim 1: Evaluate bronchial microdialysis for continuous and dynamic monitoring of the time-
to-time changes in the composition of the ELF by lactate and FD-4 in a pig model. Evaluate 
arteriobronchial urea gradient as a correction factor. 
In Paper I we evaluated Bronchial microdialysis in a pig model with standardized conditions. 
Lactate and FD-4 clamp were established at two levels. A method for standardized application 
of bronchial microdialysis was developed, see figure 4. Lactate and FD-4 could be measured 
in the bronchial microdialysate. However the precision of the measurements could have been 
better. The coefficients of variation were 60-65 percent without correction. With correction by 
the arteriobronchial urea-gradient the precision for lactate improved significantly with a 
coefficient of variation of 17 percent. For FD-4 the improvement in precision was not 
significant. 
Paper I led up to the conclusion that bronchial microdialysis could be a method to measure 
substantial concentration changes of molecules in the bronchial ELF, and that correction by 
the arteriobronchial urea-gradient improved the precision of the method. 
Aim 2: To determine if bronchial microdialysis can identify the immediate inflammatory 
response in the bronchi as measured by IL-1, IL-8, and TNF and monitor the time-to-time 
changes of these cytokines during the first 4 h of reperfusion after intestinal ischemia in a pig 
model. 
In Paper II we found increased IL-1 and IL-8 during the first 60 minutes of reperfusion in 
the bronchial ELF as a response to intestinal IR-injury in our pig-model. We could not 
reliably measure TNF. This could be caused by a high limit of detection of 100 pg/ml. In 
Paper III we measured TNF in both blood and bronchi with concentrations below 30 pg/ml. 
In Paper III the limit of quantification was below 1 pg/ml. Microdialysis of proteins such as 
cytokines have limitations caused by a relatively low relative recovery and this limits the 
possibility to measure low concentrations of large proteins. The improving sensitivity of 
multiplexed ELISAs reduce this issue, but still it requires attention. 
In Paper II lung biopsies did not show signs of diffuse alveolar injury, and FD-4 
measurements were the same in the IR-injury and he control group. We concluded that 
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bronchial cytokines occurred as an immediate response to intestinal IR before manifest organ 
failure and that bronchial microdialysis could be an early continuous monitor of the 
inflammatory response. A future issue would be to see if this method could expedite clinical 
judgment and intervention with improved outcome as a consequence. 
Aim 3: To investigate a broad spectrum of the bronchial and systemic inflammatory response 
in a time relation to the phases of open AAA repair and the immediate postoperative period 
by measuring 18 cytokines by microdialysis. 
In Paper III a broad spectrum of eighteen cytokines were measured in blood and bronchi in 
sixteen open AAA repair patients. With the application of bronchial microdialysis in a human 
model new methodological challenges came along. The method had to be totally revised and a 
modified device was developed, see figure 10. In Paper III we found that venous 
microdialysis reliably could detect the systemic inflammatory response as measured by 
cytokines. Cytokines measured by bronchial microdialysis detected the inflammatory 
response. All but one bronchial cytokine in our material were increased in patients suffering 
organ failure in direct time-relation to open AAA repair. Paper III, the human study, partially 
addresses the issue of expedited clinical judgement. Paper III indicated that early continuous 
monitoring of cytokines could be of value if the results were presented close to real time. 
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Issues for future research 
The method of bronchial microdialysis has proven useful in this thesis. Still the method needs 
further validation. The most critical issue is to verify a good method to correct for the amount 
of microdialysis membrane in contact with the bronchial ELF. Urea-correction is validated in 
microdialysis earlier up against the no net flux method for measurements in muscle and 
fat[106]. The validity of urea-correction as a parameter of membrane in contact with the 
bronchial ELF in Paper I indicate that it is useful, but it is not yet finally verified. 
The microdialysis method allows continuous follow up of inflammatory markers in controlled 
trials on treatments in intubated patients. The inflammatory process is important both in the 
diagnosis, but also in the prognosis. Patients with similar premorbid status have different 
outcome when exposed to standardized trauma. Our present research indicated that 
microdialysis could improve the methodology with continuous sampling and better spatiality. 
Our new research application of microdialysis in bronchi has a potential to add new 
knowledge. Patient groups of special interest are patients undergoing major surgery, trauma 
patients and medical and surgical intensive care patients. 
For application as a clinical diagnostic tool one technical obstacle is the time from sample 
collection to laboratory-result. The potential of close to real time monitoring of cytokines 
must be brought to attention for the developers of analysis equipment. This is a necessary step 
for clinical application. 
Our research models did not alter lung permeability according to the recorded data, but in a 
model of altered permeability in the bronchial/alveolar epithelium it may be that bronchial 
microdialysis can prove useful in experimental settings. The ability to measure continuously 
with good time spatiality in vivo can prove useful.  
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Abstract
Background: Contents of the epithelial lining fluid (ELF) of the bronchi are of central interest in
lung diseases, acute lung injury and pharmacology. The most commonly used technique
broncheoalveolar lavage is invasive and may cause lung injury. Microdialysis (MD) is a method for
continuous sampling of extracellular molecules in the immediate surroundings of the catheter. Urea
is used as an endogenous marker of dilution in samples collected from the ELF. The aim of this study
was to evaluate bronchial MD as a continuous monitor of the ELF.
Methods: Microdialysis catheters were introduced into the right main stem bronchus and into the
right subclavian artery of five anesthetized and normoventilated pigs. The flowrate was 2 Pl/min and
the sampling interval was 60 minutes. Lactate and fluorescein-isothiocyanate-dextran 4 kDa (FD-4)
infusions were performed to obtain two levels of steady-state concentrations in blood. Accuracy
was defined as [bronchial-MD] divided by [arterial-MD] in percent. Data presented as mean ± 95
percent confidence interval.
Results: The accuracy of bronchial MD was calculated with and without correction by the
arteriobronchial urea gradient. The arteriobronchial lactate gradient was 1.2 ± 0.1 and FD-4
gradient was 4.0 ± 1.2. Accuracy of bronchial MD with a continuous lactate infusion was mean
25.5% (range 5.7–59.6%) with a coefficient of variation (CV) of 62.6%. With correction by the
arteriobronchial urea gradient accuracy was mean 79.0% (57.3–108.1%) with a CV of 17.0%.
Conclusion: Urea as a marker of catheter functioning enhances bronchial MD and makes it useful
for monitoring substantial changes in the composition of the ELF.
Background
The epithelial lining fluid of the lung is important in the
understanding mechanisms in acute lung injury, inflam-
matory lung diseases, cardiac failure, and in pharmacoki-
netic studies.
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Today there are no established methods of direct continu-
ous monitoring of the epithelial lining fluid of the lower
respiratory tract. The epithelial lining fluid of the bronchi
has been examined by bronchioalveolar lavage (BAL),
direct aspiration, microsampling, and exhaled breath con-
densates. BAL and other bronchoscopic techniques have
in common that they are invasive, may create lung injury,
are based on single or intermittent samples and therefore
have limited value as continuous and dynamic monitors
of the epithelial lining fluid of the lung. The exhaled
breath condensates technique is non-invasive and contin-
uous, but is indirect and best suited for collection of non-
volatile hydrophilic solutes[1].
Microdialysis is a method for continuous sampling of
extracellular molecules in the immediate surroundings of
the catheter. The technique is based on the principle of
diffusion of substances along a concentration gradient
through a semipermeable membrane on a thin catheter
with an outer diameter of 0.6 mm. Microdialysis has rou-
tinely been used in parenchymatous organs and tissues,
but has also gained widespread acceptance in hollow
organs. Intestinal endoluminal microdialysis has been
used as a continuous monitor of intestinal dysfunction
both in experimental [2-4] and in clinical settings[5]. As
far as we know there is only one published article on
bronchial microdialysis in rats for pharmacokinetic meas-
urements of aminoglycosides[6]. The value of microdialy-
sis as a continuous and dynamic monitor of the time to
time changes in the epithelial lining fluid has not previ-
ously been evaluated.
The recovered amount of epithelial lining fluid by various
techniques, especially BAL, has been estimated by endog-
enous and exogenous markers of dilution. Urea (60 Da) is
a small molecule in equilibrium in all body compart-
ments. The recovered concentration of urea has been used
as an indicator of the recovered concentration of epithe-
lial lining fluid in the dialysate [7-10]. The arteriobron-
chial urea gradient has been used to calculate the absolute
concentration of the molecules measured in the epithelial
lining fluid by BAL and the ureagradient has also been
used to calculate the absolute concentration of molecules
measured in the extracellular fluid[9,11].
Lactate (90 Da) is a small molecule which has previously
been studied as a marker of intestinal barrier dysfunc-
tion[2]. In the intestines lactate only passes the blood-
luminal barrier of the intestines when the intestines suffer
an ischemia-reperfusion injury[4]. The question is if lac-
tate freely passes the blood-bronchial barrier.
Molecular transport across rat epithelial monolayer by the
paracellular route has previously been investigated with
the macromolecule fluorescein isothiocyanate dextran
4000 Da (FD-4)[12,13]. According to the present litera-
ture an increased leakage of FD-4 is believed to be via the
paracellular route by changes in the composition and con-
firmation of the tight junctions of the epithelium and the
endothelium in response to stimuli[14,15]. In this study,
we used FD-4 to see if larger molecular size influences the
gradient across the paracellular blood-bronchial barrier.
The aim of our study was to evaluate bronchial microdial-
ysis as a possible method for continuous and dynamic
monitoring of the time to time changes in the composi-
tion of the epithelial lining fluid. Lactate and FD-4 were
measured during two levels of steady-state concentrations
in anesthetized pigs under positive pressure ventilation.
Arteriobronchial urea gradient was used as a correction
factor to calculate the absolute concentration of lactate
and FD-4 in the bronchial epithelial lining fluid.
Methods
Anesthesia and surgical preparation
Five outbred pigs (Norwegian Landrace 50%, Duroc 25%,
Yorkshire 25%) (range 22–31 kg) were acclimatized and
treated in accordance with the "European Convention for
the Protection of Vertebrate Animals used for Experimen-
tal and Other Scientific Purposes", Strasbourg,
18.III.1986. The pigs fasted overnight with free access to
water prior to the experiment. They were premedicated
with intramuscular diazepam 10 mg (Stesolid, Dumex-
Alpharma, Copenhagen, Denmark) and azaperon 400 mg
(Stresnil, Janssen-Cilag, Vienna, Austria), and anesthesia
was induced with atropine 1 mg (Nycomed Pharma AS,
Oslo, Norway), ketamin HCl 10 mg/kg (Parke-Davis,
Solna, Sweden) and thiopenthal sodium 10 mg/kg (Pen-
tothal, Abbot Scandiavia AB, Solna, Sweden).
Tracheostomy was performed with the pig in the supine
position, and an endotracheal tube 8.0 was inserted 5 cm.
The pigs received total intravenous anesthesia with a con-
tinuous infusion of fentanyl 20 to 30 Pg/kg/hour (Fenta-
nyl, Pharmalink, Spanga, Sweden) and ketamin HCl 8 to
12 mg/kg/hour. Pancuronbromide 2 mg/ml (Pavulon,
Organon Teknika, Baxtel, The Netherlands) was used as
needed to eliminate spontaneous ventilation.
The pigs were ventilated in pressure control mode with a
positive end expiratory pressure of 7 cmH2O, a peak
inspiratory pressure less than or equal to 20 cmH2O and
a tidal volume of 6 to 8 ml/kg (Servo Ventilator 900C, Sie-
mens-Elema, Sweden)[16,17].
After a recruitment maneuver of 3 breaths at 40 cmH2O,
respiratory rate was adjusted to an arterial partial pressure
of carbon dioxide (PaCO2) of 4.5 to 5.5 kPa in baseline.
Fraction of inspired oxygen (FiO2) was maintained at 25%
Respiratory Research 2007, 8:78 http://respiratory-research.com/content/8/1/78
Page 3 of 11
(page number not for citation purposes)
during the experiment. Similar recruitment maneuvers
were performed when the bronchial microdialysis cathe-
ter was in position. In 2 out of 5 pigs a recruitment
maneuver was necessary during the experimental protocol
due to spontaneous ventilation in conflict with the venti-
lator and derecruitment. This was solved with pancuro-
nium bromide, increased infusion of the anesthetetic
agents and a recruitment maneuver to reestablish the lung
compliance as measured by lung tidal volume/peak
inspiratory measure.
The pigs received an intravenous infusion of heated
(37°C) Ringers acetate at 14 to 18 ml/kg/hour throughout
the experiment. Rectal temperature was maintained
within the normal range (37 to 39.6°C) by a heating mat-
tress[18].
The right femoral artery was cannulated with a triple
lumen catheter (Certofix-Trio S715, Braun, Melsungen,
Germany) for sampling of arterial blood gases and inva-
sive blood pressure monitoring (Tram-rac 4A/Tram-scope
12C, Marquette Electronics, USA). A single lumen catheter
(Sekalon-T 16G, Becton Dickinson, Singapore) was
inserted in the femoral vein for blood sampling. The right
carotid artery and the right jugular vein were surgically
prepared. A pulmonary artery catheter (Swan Ganz
CCOmbo 7.5 Fr, Edwards Lifescience, USA) was inserted,
and positioned using the pulmonary arterial blood pres-
sure curve and the pulmonary artery wedge pressure curve.
Continuous cardiac output and central venous saturation
were monitored (Vigilance, Edwards Lifescience, USA).
Microdialysis
Alongside the 8.0 endotracheal tube a 4.0 endotracheal
tube was inserted into the trachea and advanced to a posi-
tion 1 cm proximal to the carina confirmed by fiberoptic
bronchoscopy. A thread was used to secure the two tra-
cheal tubes and to avoid air leakage. The microdialysis
catheter (CMA Custom made, 10 mm membrane length,
100 kDa cut-off, outer diameter 0.6 mm, CMA Microdial-
ysis, Stockholm, Sweden) was introduced through the 4.0
endotracheal tube and guided fiberoptically into the left
main stem bronchus. The microdialysis catheter was gen-
tly guided forward until wedged and then retracted 0.5 to
1 cm to avoid atelectasis. The proximal opening of the 4.0
endotracheal tube was sealed with wax to avoid air leak-
age.
Another microdialysis catheter (CMA Custom made, 10
mm membrane length, 100 kDa cut-off, outer diameter
0.6 mm, CMA Microdialysis, Stockholm, Sweden) was
inserted into the right subclavian artery through a venous
catheter (Optiva2 18G, Medex, Great Britain) in the right
brachial artery.
Both microdialysis catheters were connected to microdial-
ysis pumps (CMA 107, CMA Microdialysis AB, Stock-
holm, Sweden) and perfused by sterile phosphate
buffered saline (PBS) at a flow rate of 2 Pl/min.
The microdialysis catheters were perfused with a flow of 2
Pl/min. The volume on the inside of the membranous
part of the microdialysis catheters used in this study was
less than 1.4 Pl. Thus the time period of membrane con-
tact of the microdialysis perfusion fluid was short.
The catheters were perfused in situ for t60 minutes before
the experiment was started. Samples from each microdial-
ysis catheter were collected in microvials that were
exchanged every 60 minutes, and analyzed online for lac-
tate and urea on the CMA 600 (CMA Microdialysis AB,
Stockholm, Sweden), using the peroxidase methodology.
To verify the position of the catheter at the end of the
experiment, the microdialysis catheter either was perfused
with methylene blue and the bronchial tree dissected or
the catheter was left in situ and the bronchial tree dis-
sected (figure 1).
Experimental protocol
After surgical preparations the animals were allowed to
stabilize for 60 minutes.
Lactate
An infusion of sodium lactate ~50% (Merck KGaA, Darm-
stadt, Germany) was adjusted to an arterial blood lactate
The microdialysis catheter in situFigure 1
The microdialysis catheter in situ. The picture shows 
the microdialysis catheter in the distal bronchus. The distal 
white part is the microdialysis membrane. It is this part of the 
catheter that is in contact with the epithelial lining fluid and 
collects molecules by diffusion.
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concentration of ~5 mmol/l for 120 minutes. Thereafter,
the infusion rate was increased to an arterial blood lactate
concentration of ~10 mmol/l (figure 2). Arterial blood
was collected every 15 minutes throughout the experi-
ment to establish a steady-state of lactate and PaCO2
(ABL700, Radiometer Copenhagen, Denmark).
Fluorescein isothiocyanate dextran 4000 Da infusion
A solution of FD-4 (Sigma Chemical, St. Louis, MO, USA)
in PBS was prepared fresh each day at a concentration of
10 mg/ml. The FD-4 infusion started with an intravenous
loading dose of 10 mg/kg over 10 min followed by an
infusion of 5 mg/kg/hour for 180 minutes. Then parallel
to the FD-4 infusion at 5 mg/kg/hour a new bolus of 10
mg/kg was given. After the bolus the infusion was
increased to 10 mg/kg/hour for the last 180 minutes of the
experiment (figure 3).
Beginning during in the stabilizing period, 0.5 ml of arte-
rial blood was sampled every 60 minutes throughout the
experiment. Fluorescence of plasma and microdialysate
samples was measured on a fluorescence spectrophotom-
eter (Fluoroskan II, Labsystem).
Arteriobronchial urea gradient
Urea concentrations are the same throughout various
body compartments. The arteriobronchial urea gradient
in each sampling period is a measure of the microdialysis
catheter functioning in the bronchial as opposed to the
arterial compartment.
In vivo recovery
Blood lactate was measured every 30 minutes. Mean arte-
rial blood concentration of lactate during a 60-minutes
period was defined as the mean of the value at 0, 30 and
60 minutes for the period.
Arterial blood FD-4 was measured every 60 minutes.
Mean arterial blood concentration of FD-4 during a 60-
minutes period was defined as the mean of the value at 0
and 60 minutes for the period
Overview of the fluorescein isothiocyanate dextran 4000 Da (FD-4) infusion with two steady statesFigure 3
Overview of the fluorescein isothiocyanate dextran 
4000 Da (FD-4) infusion with two steady states. Data 
are presented as mean FD-4 values by arterial microdialysis 
(solid line) with mean values in steady state (filled triangles), 
bronchial microdialysis (long dash line) with mean values in 
steady state (filled circles) and ureacorrected bronchial 
microdialysis (dash-dot line) with mean values in steady state 
(open circles). The circles and the triangles represent the 
time where the microdialysis vials were exchanged for the 
steady state samples. The gray area is a graphical presenta-
tion of the intravenous FD-4 infusion. The infusion was 
started with an intravenous bolus of 10 Pg/kg over 10 min-
utes. In the low steady state an infusion of FD-4 at 5 Pg/kg/
hour was maintained. After the low steady state a new intra-
venous FD-4 bolus of 10 Pg/kg over 10 minutes was infused. 
In the high steady state an infusion of FD-4 at 10 Pg/kg/hour 
was maintained.
Overview of the lactate infusion with two steady statesFigure 2
Overview of the lactate infusion with two steady 
states. Data are presented as mean lactate values by arterial 
microdialysis (solid line) with mean values in steady state 
(filled triangles), bronchial microdialysis (long dash line) with 
mean values in steady state (filled circles) and ureacorrected 
bronchial microdialysis (dash-dot line) with mean values in 
steady state (open circles). The circles and the triangles rep-
resent the time where the microdialysis vials were 
exchanged for the steady state samples. The gray area is a 
graphical presentation of the intravenous lactate infusion. 
During the low steady state the infusion of sodium lactate 
was gradually increased to maintain an arterial blood lactate 
of ~5 mmol/L. During the high steady state the infusion of 
sodium lactate was increased to maintain an arterial blood 
lactate of ~10 mmol/L.
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Arterial microdialysis was sampled over the same 60-
minute period.
In vivo recovery was calculated as [Molecule]arterial microdial-
ysis/[Molecule]arterial blood.
In vitro microdialysis
Lactate wells were prepared in PBS at lactate concentra-
tions of ~1, ~5 and ~10 mmol/L. Three microdialysis cath-
eters (CMA20, 10 mm membrane length, 100 kDa cut-off,
outer diameter 6 mm, CMA microdialysis, Stockholm,
Sweden) were perfused with PBS at 2 Pl/min and put in
the first well, lactate ~1 mmol/L, for 60 minutes to stabi-
lize. Thereafter vials were exchanged every 60 minutes for
180 minutes. Samples from the wells were collected and
analyzed at the beginning and at the end of the experi-
ment. The procedure was then repeated for lactate ~5 and
~10 mmol/L. All lactate samples were analyzed on the
CMA 600 (CMA Microdialysis AB, Stockholm, Sweden).
The procedure was repeated for FD-4 wells prepared with
PBS at FD-4 concentrations of ~10, ~50 and ~150 Pg/ml.
This setup gave good and stable volume recovery with FD-
4 samples being analyzed in triplicate or quadruplicate,
each well containing 25 Pl (Fluoroskan II, Labsystem).
In vitro recovery was calculated as [Molecule]well microdialy-
sis/[Molecule]well.
Statistics and calculations
Arterial microdialysis values were considered to be the
real arterial concentration during each sample period.
Bronchial values are presented with and without correc-
tion by the arteriobronchial urea gradient. Ureacorrection
was done in accordance to the formula in Rennard's arti-
cle[9]. ([Urea]arterial/[Urea]bronchial)/([Molecule]arterial/
[Molecule]bronchial).
Evaluation of bronchial microdialysis and urea-corrected
bronchial microdialysis as an approximation of arterial
microdialysis are presented as accuracy. The bronchial
microdialysis values, corrected and uncorrected, are pre-
sented as fractions of the arterial microdialysis values.
Accuracy = [Molecule]bronchial/[Molecule]arterial. To evalu-
ate the benefit of the urea correction, the coefficient of var-
iation was used. Coefficient of variation = Standard
deviation/Mean·100.
Calibrations of the microdialysis catheters were done by
in vitro experiments and in vivo calculations. In vitro rel-
ative recovery = [Molecule]well microdialysis/[Molecule]well. In
vivo relative recovery = [Molecule]arterial microdialysis/[Mole-
cule]arterial blood.
The data are presented as values and mean ± 95% confi-
dence interval. Paired t-test was used to compare means
between arterial, bronchial and urea-corrected bronchial
microdialysis with significance defined as p < 0.05.
Results
Circulatory and respiratory measurements
Heart rate, mean artery pressure, cardiac output, central
venous oxygen saturation and partial pressure of carbon-
dioxide remained stable throughout the entire experiment
(table 1).
Recovery measurements
The in vivo lactate relative recovery was 105.9 ± 7.2%. The
in vivo FD-4 relative recovery was 28.8 ± 4.4%.
The in vitro lactate relative recovery was 54.9 ± 3.2%. The
in vitro FD-4 relative recovery was 14.2 ± 1.0%.
Arteriobronchial urea gradient
Arterial urea by microdialysis was 3.69 ± 0.59 mmol/L.
Bronchial urea by microdialysis was 1.19 ± 0.21 mmol/L.
Arteriobronchial urea gradient was 3.78 ± 0.85.
Lactate
During the steady-state periods lactate measured by arte-
rial microdialysis was 6.5 ± 0.9 and 11.8 ± 1.4 mmol/L, by
bronchial microdialysis 1.5 ± 0.8 and 3.0 ± 0.9 mmol/L
and by urea-corrected bronchial microdialysis 5.5 ± 0.8
and 9.6 ± 1.3 mmol/L respectively. There was an arterio-
bronchial gradient of 1.2 ± 0.1 for lactate as measured by
arterial microdialysis and bronchial microdialysis, cor-
rected by the arteriobronchial urea gradient. Steady-state
values and mean values for arterial lactate, bronchial lac-
Table 1: Central hemodynamic and respiratory variables.
Parameter Stabilizing Low steady state High steady state
Mean arterial pressure (mmHg) 65 ± 3 64 ± 2 60 ± 1
Heart rate (beats/min) 81 ± 15 88 ± 6 89 ± 3
Cardiac output (l/min) 4.2 ± 0,9 4.8 ± 0.4 4.9 ± 0.4
Central venous oxygen saturation (percent) 59 ± 5 62 ± 3 60 ± 3
Arterial partial pressure of carbon dioxide (kPa) 4.81 ± 0.23 4.78 ± 0.09 4.94 ± 0.11
Values are mean ± 95% confidence interval.
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tate and urea-corrected bronchial lactate, as measured by
microdialysis are presented in figure 4. Paired t-test show
a significant difference (p < 0.05) between lactate by arte-
rial microdialysis and urea-corrected bronchial microdial-
ysis at low steady state (blood lactate ~5 mmol/L).
The accuracy of bronchial microdialysis with a continuous
lactate infusion was mean 0.26 ± 0.08 with a coefficient of
variation of 62.6%. The accuracy of bronchial microdialy-
sis with a continuous lactate infusion and a correction by
the arteriobronchial urea gradient was mean 0.81 ± 0.06
with a coefficient of variation of 17.0% (figure 5). The
reduction in the coefficient of variation is in accordance
with urea being a molecule in almost immediate equilib-
rium within all body compartments and thereby is a cor-
rection factor of bronchial microdialysis catheter
functioning.
Non-microdialysis data are presented in table 2.
Fluorescein isothiocyanate dextran 4000 Da
During the steady-state periods FD-4 measured by arterial
microdialysis was 6.5 ± 1.9 and 16.0 ± 4.0 Pg/ml, by bron-
chial microdialysis 0.7 ± 0.3 and 1.2 ± 0.5 Pg/ml and by
urea-corrected bronchial microdialysis 2.2 ± 0.6 and 5.3 ±
2.5 Pg/ml respectively. There was an arteriobronchial gra-
dient of 4.0 ± 1.2 for FD-4 as measured by arterial micro-
dialysis and bronchial microdialysis, corrected by the
arteriobronchial urea gradient. Steady-state values and
means for arterial FD-4, bronchial FD-4 and ureacorrected
bronchial FD-4, as measured by microdialysis, are pre-
sented in figure 6. There was a defined barrier between
blood and bronchi for the diffusion of FD-4.
The accuracy of bronchial microdialysis with a continuous
FD-4 infusion was mean 0.09 ± 0.03 with a coefficient of
variation of 65.2%. The accuracy of bronchial microdialy-
sis with a continuous FD-4 infusion and a correction by
the arteriobronchial urea gradient was mean 0.35 ± 0.10
with a coefficient of variation of 54.8%. The reduction in
the coefficient of variation was less than expected. Previ-
ous knowledge of FD-4 analyses on the Fluoroskan II is
Accuracy of bronchial microdialysis of lactateFig e 5
Accuracy of bronchial microdialysis of lactate. All val-
ues (gray circles) and mean (-) are presented. One value 
(open circle) is excluded as an outlier due to extreme devia-
tion in the arterial microdialysis value. The accuracy of bron-
chial microdialysis with a continuous lactate infusion was 
mean 0.26 ± 0.08 with a coefficient of variation of 62.6%. The 
accuracy of bronchial microdialysis with a continuous lactate 
infusion and a correction by the arteriobronchial urea gradi-
ent was mean 0.81 ± 0.06 with a coefficient of variation of 
17.0%. The reduced coefficient of variation after correction 
by the arteriobronchial ureagradient sustains the ureacorrec-
tion as useful correction factor to estimate the absolute con-
centrations of molecules in the epithelial lining fluid as 
measured by microdialysis.
Microdialysate lactateFigure 4
Microdialysate lactate. All values (gray circles) and mean 
(-) are presented. Lactate values by corrected bronchial 
microdialysis are corrected by the arteriobronchial urea gra-
dient. * Paired T-test showed significant difference from arte-
rial microdialysis at low steady state (arterial blood lactate 
~5 mmol/L) (p < 0.05). † Paired t-test showed significant dif-
ference from arterial microdialysis at high steady state (arte-
rial blood lactate ~10 mmol/L) (p < 0.05). ns Non significant 
from arterial microdialysis at high steady state (arterial blood 
lactate ~10 mmol/L).
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from experiments with wells containing 150 Pl. Due to
small volumes sampled by microdialysis, pilot in vitro
studies were conducted with wells containing 15 Pl, 25 Pl
and 40 Pl. With wells containing 15 Pl there was a great
variance and by visual inspection we saw that this small
volume did not cover the bottom of the well. Wells con-
taining 25 Pl and 40 Pl gave similar results and variance
(data not shown). During analysis of the last fluorescein
isothiocyanate results from the in vivo experiment, we
registered that wells with higher concentrations of FD-4
increased the registered result of neighboring wells with
lower concentration of FD-4. Due to lack of material the
analysis could not be repeated and controlled.
Non-microdialysis data are presented in table 2.
Individual correlation
To evaluate bronchial microdialysis as a tool of continu-
ous monitoring all pigs are presented in XY-plots with
individual values and correlation lines (figure 7). There
was a significant improvement in the correlation between
urea-corrected bronchial and arterial lactate values versus
bronchial and arterial lactate values by paired t-test. For
fluorescein isothiocyanate, the improvement was only a
tendency and did not reach significance.
Discussion
Extensive research on the bronchial epithelial lining fluid
has been done to understand mechanisms of permeabil-
ity, pharmacokinetics and pathophysiology. The lack of
techniques for continuous monitoring and the possibility
of causing lung injury have limited previous work to
describe the dynamics of physiological phenomena. Lung
microdialysis as previously described, with an open surgi-
cal technique and "interstitial" introduction of the micro-
dialysis catheter by visual control, is only suitable for
patients undergoing thoracic surgery [19-21].
This study indicates that bronchial microdialysis can be
used as a continuous monitor of the epithelial lining
fluid. Correction of bronchial microdialysis by the arteri-
obronchial urea gradient enhances bronchial microdialy-
sis, as measured by lactate, by reducing the coefficient of
variation. Correction by the arteriobronchial urea gradi-
ent makes bronchial microdialysis suitable as a monitor
of substantial concentration changes in the epithelial lin-
ing fluid.
There is an ongoing controversy on how to estimate the
amount of epithelial lining fluid recovered. Urea rapidly
diffuses and equilibrates into the total volume sampled
with BAL technique. Therefore recovered concentration of
urea as a marker of recovered concentration of epithelial
lining fluid has a tendency to overestimate the recovered
concentration of epithelial lining fluid and hence under-
estimate the bronchial concentration of the measured
molecule. Total BAL volumes in humans vary from 100 to
300 ml[9,22]. The tendency of overestimating the recov-
ered volume of epithelial lining fluid also increases with
increasing dwell time with BAL technique. The dwell time
of BAL varies from about 3 to more than 10 minutes.
Technetium-99 m diethylenetriaminepenta-acetic acid
has been used as an alternative marker of recovered con-
centration of epithelial lining fluid without the problem
Microdialysate fluorescein isothiocyanate dextran 4000 DaFigure 6
Microdialysate fluorescein isothiocyanate dextran 
4000 Da. All values (gray circles) and mean (-) are pre-
sented. Fluorescein isothiocyanate dextran 4000 Da (FD-4) 
values by corrected bronchial microdialysis are corrected by 
the arteriobronchial urea gradient. * Paired t-test showed 
significant difference from arterial microdialysis at low steady 
state (FD-4 5 Pg/kg/hour) (p < 0.05). † Paired t-test showed 
significant difference from arterial microdialysis at high steady 
state (FD-4 10 Pg/kg/hour) (p < 0.05).
Table 2: Non-microdialysis data.
Parameter Low steady state High steady state
Lactate (mmol/L) 5.9 ± 0.4 11.2 ± 0.3
Fluorescein isothiocyanate 
dextran 4000 Da (Pg/ml)
25.2 ± 3.8 49.5 ± 6.7
Lactate was measured in blood and fluorescein isothiocyanate 
dextran 4000 Da was measured in plasma. Non-microdialysis data 
are intermittent samples and not continuous measurements. Values 
are mean ± 95% confidence interval.
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of additional influx in the instilled lavage volume[23].
However the method is time consuming and this limits its
applicability in both clinical and experimental settings.
With small volume lavage (3 aliquots of 1 ml) with short
dwell time (less than 1 minute) urea is a valid marker of
dilution in BAL fluids in both the normal, diseased and
recovering lung in infants, according to Dargaville et al[7].
With microdialysis, the additional volume to equilibrate
was minimal (less than 1.4 Pl), limited to the volume on
the inside of the semi-permeable membrane of the cathe-
ter. With a perfusion flow of 2 Pl/minute and the short
time period of contact between the microdialysis per-
fusion fluid and the epithelial lining fluid, the arterio-
bronchial urea gradient was a reasonable correction factor
XY-plot of bronchial and corrected bronchial microdialysis data against arterial microdialysis data of lactate and fluorescein iso-thiocyanate dextran 4000 DaFigure 7
XY-plot of bronchial and corrected bronchial microdialysis data against arterial microdialysis data of lactate 
and fluorescein isothiocyanate dextran 4000 Da. All five pigs are represented; number one closed circles and line, 
number two open circles and dotted line, number three closed triangles and medium dashed line, number four open triangles 
and dash-dot-dot line, and number five closed squares and long dashed line. Plot A and B show arterial lactate along the X-axis 
and bronchial (R2 0.82 ± 0.18) and ureacorrected bronchial lactate (R2 0.91 ± 0.11) along the Y-axis respectively. Paired t-test 
of R2 for the individual bronchial and ureacorrected bronchial lactate XY-plots showed significant difference (p < 0.05). Plot C 
and D show arterial fluorescein isothiocyanate dextran 4000 Da (FD-4) along the X-axis and bronchial (R2 0.53 ± 0.38) and 
ureacorrected bronchial FD-4 (R2 0.72 ± 0.34) along the Y-axis. Paired t-test of R2 for the individual bronchial and ureacor-
rected bronchial FD-4 XY-plots was not significant.
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for the recovered concentration of epithelial lining fluid.
Thus it could be a correction factor to calculate the abso-
lute concentrations of lactate and FD-4 in the epithelial
lining fluid[7,10,11,23].
In vivo studies of transport of molecules are complicated
by the metabolic activity of the organism. Molecules will
to some extent be depositioned both extra- and intracell-
uarly. Metabolism in all tissues and renal clearance of the
molecule one measures are factors that must be corrected
and/or considered when the conclusions are drawn.
Lactate is depositioned in all body compartments, espe-
cially red blood cells and muscle[24]. The lung itself is a
possible producer of lactic acid[25]. Urea (60 Da) and lac-
tate (90 Da) differ in size and shape and may have differ-
ent diffusion properties over the blood-bronchial barrier.
Lactate passed the blood-bronchial barrier rather freely
with a gradient of 1.2:1. Whether the gradient is a true
blood-bronchial gradient is not known at present.
FD-4 crossed the blood-bronchial barrier with a gradient
of about 4:1. As described previously in monolayer cell
cultures of rat alveolar epithelial cells, FD-4 is transported
through paracellular pores in human cultured alveolar
epithelial cell monolayer[26]. FD-4 was chosen as a mac-
romolecule with restricted transport through paracellular
pores. Matsukawa showed this in rat alveolar epithelial
cell monolayer[12]. As far as we know there is no previous
study that describes FD-4 transport in vivo across the
blood-bronchial barrier. In our study FD-4 had to cross
intact endothelium, lung interstitium and lung epithe-
lium. Due to methodological limitations with small vol-
ume samples, our FD-4 results varied. The blood-
bronchial gradient was 4.0:1 ± 1.2. FD-4 was transported
across the blood-bronchial barrier with restriction, in
accordance with previous findings, but this requires fur-
ther research to be confirmed.
The arteriobronchial urea gradient as a marker of bron-
chial catheter function reduced the coefficient of variation
from 62.6% to 17.0% of the bronchial microdialysis as
measured for lactate. The arteriobronchial urea gradient
significantly improved correlation of arterial and bron-
chial lactate sampled over the same time interval in the
same pig. A coefficient of variation of 17% still limits the
use of bronchial microdialysis in the measurement of
minor changes in lactate concentration of the bronchial
epithelial fluid.
Bronchial microdialysis has some limitations. Bronchi are
relatively stiff lumens with continuous movements during
the respiratory cycle. The epithelial lining fluid is only a
thin film. Microdialysis is developed for analyzing the
composition of extracellular fluids in compact tissues
with little movement. In the bronchi, one must assume
that only varying parts of the microdialysis membrane are
in contact with the epithelial lining fluid during the respi-
ratory cycle. Thus, a marker of catheter functioning is nec-
essary for characterizing each individual microdialysis
catheter, measuring the recovered amount of epithelial
lining fluid and the absolute concentrations of the mole-
cules in the epithelial lining fluid.
With correction of bronchial microdialysis by the arterio-
bronchial urea gradient, the coefficient of variation of FD-
4 decreased only slightly, from 65.2% to 54.8%. There
was only a tendency toward improved correlation
between arterial and bronchial FD-4 sampled over the
same time interval in the same pig. The pilot studies on
concentration and variation of different volumes on fluo-
rescence spectrophotometry concluded that 25 Pl in each
well was sufficient to get precise numbers with a small
degree of variation. But the FD-4 results from our study
were not optimal with a high degree of variation. One of
the problems was that wells with high concentration of
FD-4 increased the measured FD-4 concentration in
neighboring wells with low concentration of FD-4 accord-
ing to our fluorescence spectrophotometer. This problem
could be a contributing factor to the lack of precision with
our method. The lack of reduction in the coefficient of var-
iation of FD-4 by urea correction is probably due to meth-
odological errors in analyzing FD-4 in small volumes by
fluorescence spectrophotometry. Thus FD-4 measurement
in small volumes still has to be refined to increase the pre-
cision of the method.
In vivo lactate recovery was more than 100% (105.9 ±
7.2%). The non-microdialysis samples were analyzed in
whole blood. The microdialysis probe was placed in
plasma in the subclavian artery. The plasma lactate is
higher than the lactate value in erythrocytes[27].
In our laboratory we have shown that the CMA 600 (CMA
Microdialysis AB, Stockholm, Sweden) and the ABL700
(Radiometer Copenhagen, Denmark) return different
results from the same sample with a known lactate con-
centration (data not shown). The CMA600:ABL700 ratio
for lactate in our laboratory is mean 1.13:1. The in vivo
recovery percent for lactate must be evaluated with these
factors in mind.
There was a major difference, about 2:1, between in vivo
and in vitro recovery. In vitro the microdialysis catheter
was placed in a well, collecting molecules from the imme-
diate surroundings. In general, this means that there will
always be a concentration gradient within the well around
the membrane of the microdialysis catheter. Accordingly,
there was a local concentration gradient and a smaller
concentration of the measured molecule in the immediate
Respiratory Research 2007, 8:78 http://respiratory-research.com/content/8/1/78
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surroundings of the microdialysis catheter. This effect
increased with increasing perfusion volume per time unit.
2 Pl/min is a relatively high perfusion rate with the micro-
dialysis technique. In vivo, the catheter was in the arterial
bloodflow with a continuous replacement of the fluid sur-
rounding the microdialysis membrane so that the concen-
tration of the measured molecule was the same in the
immediate surroundings of the microdialysis membrane
as in the rest of the fluid compartment.
Based on good volume recovery in the in vitro experi-
ments, an isotonic crystalloid perfusion fluid was chosen.
A microdialysis membrane with 100 kDa cut-off has large
pores which easily can contribute to a loss of collected vol-
ume limiting the possibility for analyzing triplicates. The
literature indicates that use of a colloid perfusion fluid
increases the recovered volume, but has no significant
influence on the concentration of the sampled molecules
at a perfusion rate of 2 Pl/min[28]. Thus a colloid per-
fusion fluid would probably increase the recovered vol-
ume and more frequently allow triplicate analyses of each
sample and larger volumes in each analysis.
The method as presented in this study is well suited for
monitoring substantial changes in the composition of the
epithelial lining fluid as seen with major physiological
trauma such as sepsis and ischemia-reperfusion injury,
and may even be used in the clinical setting. Combining
the application of microdialysis in the bronchi with
present knowledge of the microdialysis technique can
provide better knowledge of the dynamics of the epithe-
lial lining fluid in normal (pharmacokinetics) and patho-
logical processes (altered permeability and measurement
of markers of inflammation).
Conclusion
Bronchial microdialysis is an applicable continuous mon-
itor of the dynamic changes in the composition of the epi-
thelial lining fluid. The absolute concentrations of the
measured molecules can be estimated with acceptable
precision using a correction by the arteriobronchial urea
gradient.
Further research on bronchial microdialysis has to be
done.
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